<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2308234030
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1992
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ULTRAVIST 370
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IOPROMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        769
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1066.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BAYER AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BAYER AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 392]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL-KAMAL IMPORT OFFICE CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BAYER AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        NA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:0in; margin-right:0in; text-align:left">Ultravist-370 is an iodine-containing, monomeric, non-ionic X-ray contrast medium.</p><p style="margin-left:0in; margin-right:0in; text-align:left">Iodine absorbs X-rays, which makes it easier to view the areas of the body where Ultravist-370 is present.</p><p style="margin-left:0in; margin-right:0in; text-align:left">The contrast medium will be given to you by trained healthcare professionals.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Ultravist-370 is used for:</p><p style="margin-left:0in; text-indent:0in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->X-ray imaging of blood vessels (angiography, intra-arterial digital subtraction angiography)</p><p style="margin-left:0in; margin-right:0in; text-align:left; text-indent:0in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->enhancing the contrast of computer tomography (CT)</p><p style="margin-left:0in; margin-right:0in; text-align:left; text-indent:0in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->imaging of the kidneys and lower urinary tract (urography)</p><p style="margin-left:0in; margin-right:0in; text-align:left; text-indent:0in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->imaging of body cavities (exception: myelography, ventriculography, cisternography).</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Ultravist-370 is used for diagnostic purposes.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:0in; margin-right:0in; text-align:left">In order to reduce the risk of any possible incompatibilities, your doctor/trained healthcare professional will not mix Ultravist-370 with any other medicines.</p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>Ultravist-370 should not be used</strong></p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">&nbsp;</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to iopromide or iodine, or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>Warnings and precautions</strong></p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:0in; margin-right:0in; text-align:left">Talk to your doctor or nurse before using Ultravist-370:</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after use of Ultravist-370.</p><p style="margin-left:0in; margin-right:0in; text-align:left"><u>&nbsp;</u></p><p style="margin-left:0in; margin-right:0in; text-align:left"><u>For all types of uses</u></p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p><em>Hypersensitivity reactions (allergy-like or anaphylactoid reactions)</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">Inform your doctor in the following cases:</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had a reaction to another contrast medium in the past,</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you currently have, or have had bronchial asthma or allergies,</p><p style="margin-left:0in; margin-right:0in; text-align:left">because this means you have an increased risk of having an allergy-like reaction to Ultravist-370 (including serious reactions). Your doctor will then decide whether or not the planned examination should be performed.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">After using Ultravist-370, dose-dependent allergy-like (allergoid) reactions may occur in varying severity, or even shock or various other symptoms, e.g. in the form of cardiovascular (heart and blood vessels), respiratory (airways) and cutaneous (skin) reactions.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Because such events occur so irregularly, they cannot be predicted in individual cases. Most reactions occur within one half hour of receiving the contrast medium. However, reactions can also occur later (after hours or days).</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Inform your doctor if you are taking beta-blockers, i.e. medicines that are used to treat high blood pressures. Patients taking beta-blockers may not respond to standard treatment with beta agonists (also see the subsection &quot;Other medicines and Ultravist-370&quot; in this section).</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p>Your doctor may give you corticosteroids before the examination if you have an increased risk of acute, allergy-like reaction (e.g. if you have already had a moderately severe or severe reaction, if you suffer from asthma or allergies requiring treatment).</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Also inform your doctor if you suffer from any diseases of the cardiovascular system. If a severe hypersensitivity reaction occurs, there is an increased risk for serious or even fatal consequences.</p><p>&nbsp;</p><p><em>Preparing for an emergency</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">Regardless of the quantity and type of application, minor allergoid symptoms may be the first sign of a serious anaphylactoid reaction requiring treatment. This is why contrast media containing iodine should only given at facilities where emergency treatment is available, i.e. appropriate equipment and medications, suitably trained medical staff and assistants.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Careful precautionary measures to immediately treat serious reactions are therefore should always be readily available for all patients, in addition to the necessary emergency medications and emergency instruments.</p><p>&nbsp;</p><p>After you receive Ultravist-370, your doctor will monitor you closely for at least &frac12;&nbsp;hour, since experience shows that most serious events occur within this time period.</p><p>&nbsp;</p><p><em>Serious skin reactions</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">Take special care with Ultravist-370:</p><p>Serious skin reactions including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalised exanthematous pustulosis (AGEP) have been reported in association with Ultravist-370 use. Seek medical attention immediately if you notice any of the signs described in section&nbsp;4.</p><p>&nbsp;</p><p><em>Thyroid function disturbances</em></p><p style="margin-left:0in; text-indent:0in">X-ray contrast media containing iodine influence thyroid function by way of the free iodide contained in the solutions and the iodide that is also subsequently released in the body due to deiodination after receiving the contrast medium.</p><p style="margin-left:0in; text-indent:0in">&nbsp;</p><p style="margin-left:0in; text-indent:0in">Please inform your doctor if you suffer from a hyperfunctioning thyroid (hyperthyroidism), if it is suspected that you may have a hyperfunctioning thyroid, or if you suffer from an enlarged nodular thyroid gland. In such cases, iodine-containing contrast media may lead to thyroid hyperfunctioning or even thyrotoxic crisis (severe complications in association with an overly active thyroid gland).</p><p style="margin-left:0in; text-indent:0in">&nbsp;</p><p style="margin-left:0in; text-indent:0in">Inform your doctor if you have a medical history of a thyroid disorder, including hypothyroidism (an underactive thyroid). There have been reports of abnormal blood values in thyroid function tests after use of iodine-containing contrast media. This may indicate possible hypothyroidism or a transient (temporary) impairment of thyroid function.</p><p style="margin-left:0in; text-indent:0in">&nbsp;</p><p style="margin-left:0in; text-indent:0in">If the use of iodine-containing contrast media is planned for a patient with such risks, the patient&#39;s thyroid function must be examined prior to receiving Ultravist-370, and thyrostatic treatment should be initiated if necessary.</p><p style="margin-left:0in; text-indent:0in">&nbsp;</p><p style="margin-left:0in"><em>Thyroid Dysfunction in Pediatric Patients 0 to 3 Years of Age</em></p><p style="margin-left:0in; margin-right:0in">Thyroid dysfunction characterized by hypothyroidism or transient thyroid suppression has been reported after both single exposure and multiple exposures to iodinated contrast media. Among patients 0 to 3 years of age exposed to iodinated contrast media, thyroid dysfunction has been reported in 1% to 15% depending on the age of the patient and the dose of the iodinated contrast agent.</p><p style="margin-left:0in">Younger age, very low birth weight, prematurity, and the presence of other conditions, such as, admission to neonatal or pediatric intensive care units, and cardiac conditions are associated with an increased risk. Pediatric patients with cardiac conditions may be at the greatest risk given that they often require high doses of contrast during invasive cardiac procedures, such as catheterization and computed tomography (CT).</p><p style="margin-left:0in; margin-right:0in; text-align:left">Pediatric patients 0 to 3 years of age warrant closer monitoring because an underactive thyroid during early life may be harmful for motor, hearing, and cognitive development and may require transient T4 replacement therapy. Evaluate thyroid function in all pediatric patients 0 to 3 years of age within 3 weeks following exposure to iodinated contrast media, especially in term and preterm neonates. If thyroid dysfunction is detected, treat and monitor thyroid function as clinically needed.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p><em>Nervous system disturbances</em></p><p>During or shortly after the imaging procedure you may experience a short-term brain disorder called encephalopathy. Tell your doctor straight away if you notice any of the signs and symptoms related to this condition described in section&nbsp;4.</p><p><em>&nbsp;</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">Inform your doctor if you suffer from any CNS disorders (disorders of the central nervous system), e.g. seizures. In connection with using Ultravist-370 you may be at a higher risk for developing neurological complications. These occur more frequently during cerebral angiographies (X-ray examinations of the blood vessels in the brain) and other similar examinations.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Particular caution is indicated for patients with lower seizure thresholds, e.g. due to previous seizures and simultaneous use of certain medications.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Factors that increase the permeability of the blood-brain barrier make it easier for contrast medium to pass into brain tissue, which may result in neurological complications.</p><p>&nbsp;</p><p><em>Fluid balance of the body (hydration)</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">Ultravist-370 should not be given to you if you are dehydrated (there is not enough fluid in your body). To avoid this, your doctor will make sure that you have consumed enough fluid before your examination (see also section 2 &quot;Intravascular applications (administration into a blood vessel)&quot;).</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">This applies particularly to patients who are at an increased risk of contrast medium-associated acute kidney injury (PC-AKI) (see section&nbsp;2 &ldquo;Intravascular applications - <em>Acute kidney </em>injury&rdquo;) as well as to patients with increased urine discharge (polyuria), reduced urine discharge (oliguria), newborns, infants, small children and older patients.</p><p style="text-align:justify">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Tell your doctor if your kidney function is impaired. Your doctor will ensure that you are well hydrated before your examination. Adequate hydration by administration of a solution for injection into a vein will be considered, especially for patients with contrast medium-associated acute kidney injury (PC-AKI). The decision will be made by your doctor based on recommendations of current clinical guidelines and the individual benefit-risk ratio. The presence of any accompanying conditions will be taken into account. Tell your doctor if you have severe renal impairment associated with heart disease. Intravenous hydration (administration of an injection solution into a vein) can lead to serious complications in patients suffering from heart disease.</p><p style="text-align:justify">&nbsp;</p><p><em>Anxiety</em></p><p style="text-align:left">If you suffer from anxiety, inform your doctor prior to using Ultravist-370. Over-excitement, anxiety and pain may increase the risk for side effects or intensify contrast media-related reactions (also see section&nbsp;4 &quot;Possible side effects&quot;).</p><p>&nbsp;</p><p><em>Pretesting</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">Pretesting for hypersensitivity using a low test dose of Ultravist-370 is not recommended, inasmuch as this approach has no predictive value, and on occasion, has even led to serious and sometimes even lethal hypersensitivity reactions.</p><p style="margin-left:0in; margin-right:0in; text-align:left"><em><u>&nbsp;</u></em></p><p style="margin-left:0in; margin-right:0in; text-align:left"><u>Intravascular applications (administration into a blood vessel)</u></p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left"><em>Cardiovascular diseases</em></p><p style="text-align:left">If you are injected with Ultravist-370 for the purpose of examining your blood vessels and you have a serious circulatory disease or severe disease of the coronary vessels (oxygen undersupply of the myocardial muscle, chest pain), you have an increased risk for clinically relevant changes in blood circulation (haemodynamic changes) and for irregular heartbeat (arrhythmia). (Also see section&nbsp;3 &ldquo;How Ultravist-370 is administered - <em>Patients with impaired renal function</em>&rdquo;).</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">This applies particularly after injection of contrast media into the cardiac arteries or chambers (see section &ldquo;Possible side effects&rdquo;).</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">Patients particularly at risk for cardiac reactions are those with cardiac muscle weakness (heart failure), severe coronary heart disease, unstable angina pectoris, heart valve disease, recent myocardial infarction, coronary bypass, and high lung pressure (pulmonary hypertension). If you have suffered heart failure, the application of Ultravist-370 may lead to fluid accumulation in the lungs (pulmonary oedema).</p><p style="text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left"><em>Acute kidney injury</em></p><p style="text-align:left">There is a risk of kidney injury (contrast medium-associated acute kidney injury / PC-AKI) following the intravascular administration (administration into a blood vessel) of Ultravist-370. This can lead to temporarily disturbed kidney function. Kidney failure may occur in some patients.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">Predisposing factors include:</p><p style="margin-left:.25in; margin-right:0in; text-align:left; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->existing impairment of kidney function (renal insufficiency),</p><p style="margin-left:.25in; margin-right:0in; text-align:left; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->You can also find more information in section&nbsp;3 &ldquo;How Ultravist-370 is administered - <em>Patients with impaired renal function</em>&rdquo;,</p><p style="margin-left:.25in; margin-right:0in; text-align:left; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->dehydration,</p><p style="margin-left:.25in; margin-right:0in; text-align:left; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->diabetes mellitus,</p><p style="margin-left:.25in; margin-right:0in; text-align:left; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->cancer of bone marrow plasma cells (multiple myeloma) /</p><p style="margin-left:.25in; margin-right:0in; text-align:left">increased number of paraproteins in the blood (paraproteinaemia),</p><p style="margin-left:.25in; margin-right:0in; text-align:left; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->high doses of contrast media and/or multiple injections of Ultravist-370.</p><p style="text-align:left">&nbsp;</p><p style="margin-left:0in; text-indent:0in">Patients whose kidneys no longer function properly and who require dialysis can be given Ultravist-370 for radiological examinations, inasmuch as iodine-containing contrast media can be eliminated by means of dialysis. Haemodialysis should be carried out immediately after the radiological examination.</p><p style="margin-left:0in; text-indent:0in">&nbsp;</p><p style="margin-left:0in; text-indent:0in">In case of severe kidney failure, any additional severe functional disorder can seriously delay excretion of the contrast medium from the liver, which may require haemodialysis.</p><p style="margin-left:0in; text-indent:0in">&nbsp;</p><p style="margin-left:0in; text-indent:0in"><em>Diabetes mellitus</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">In order to avoid the increased formation of acid in the blood (lactic acidosis), diabetes mellitus patients receiving metformin treatment should have their serum creatinine levels measured before receiving an intravascular administration of an iodinated contrast medium. (see section &quot;Other medicines and Ultravist-370&quot;).</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Depending on the results of kidney function tests, a pause in taking Metformin should be considered.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">For <em><u>emergency patients</u></em> and in case of restricted or unknown renal function, physicians must carefully determine the risks versus the benefits of a contrast-enhanced examination and must also take the necessary precautions: discontinue metformin therapy, hydrate the patient, monitor renal function values, serum lactate and pH, and observe the patient closely for clinical signs of lactic acidosis.</p><p>&nbsp;</p><p><em>Disturbances of the coagulation system</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">Contrast media examinations of the blood vessels using a catheter are associated with the risk of causing vascular occlusions in the form of blood clots (thromboembolism). In addition to the contrast medium itself, numerous other factors can contribute to the development of vein blockage due to blood clots (thromboembolic events). These include: length of the examination procedure, number of injections, type of catheter and syringe materials, existing underlying diseases and concomitant medication. To minimise the examination-related risk of blocked veins due to blood clots (risk of thrombosis and embolism), examination techniques need to be conducted as carefully as possible when visualising blood vessels, the catheter needs to be flushed frequently with physiological saline solution (with the addition of heparin if possible), and the examination should be kept as short as possible.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p><em>Disturbances of the central nervous system</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">Caution should be exercised as regards intravascular administration (into the blood vessels) in patients with acute cerebral infarction or acute intracranial haemorrhage, in patients with diseases causing damage to the blood-brain barrier, as well as in patients with cerebral oedema<strong> </strong>or acute demyelinisation. For patients with brain tumours, brain metastases or epilepsy, the frequency of cerebral seizures may increase after administration of contrast media. Neurological symptoms caused by diseases of the blood vessels in the brain (cerebrovascular diseases), brain tumours or brain metastases, degenerative or inflammatory processes can be intensified by the administration of contrast media. Administration of contrast media into an artery may cause spasms of the blood vessels and the accompanying symptoms of inadequate blood supply to the brain. Patients with symptomatic cerebrovascular diseases, recent stroke or frequent transient ischaemic attacks have an increased risk of contrast media-induced neurological complications.</p><p>&nbsp;</p><p><em>Further risk factors</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">Patients with a certain disease of the adrenal gland (phaeochromocytoma) may be at increased risk of developing blood pressure crisis (hypertensive crisis) after intravascular administration (administration into a blood vessel) of the contrast medium.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">After intravascular administration (administration into a blood vessel) of the contrast medium, Ultravist-370 may intensify the symptoms of a muscle weakness disease (myasthenia gravis).</p><p style="margin-left:0in; margin-right:0in; text-align:left"><em><u>&nbsp;</u></em></p><p style="margin-left:0in; margin-right:0in; text-align:left"><u>Use in body cavities</u></p><p style="margin-left:0in; margin-right:0in; text-align:left">Patients with acutely inflamed pancreas (pancreatitis) and acutely inflamed bile ducts (cholangitis) should undergo a careful risk-benefit assessment before using Ultravist-370 for endoscopic examination of the bile and pancreatic duct (ERCP endoscopic retrograde cholangiopancreaticography). The examination must be postponed until any acute symptoms have subsided (3‑4&nbsp;weeks), unless immediate therapeutic measures such as the removal of an obstructing stone (blockage due to stone in the bile duct) or stenosis bypass are required.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:17.85pt; margin-right:0in"><strong>Other medicines and Ultravist-370</strong></p><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">Tell your doctor or pharmacist if you are taking/using, have recently taken/used or might take/use any other medicines. This also includes medicines that you do not take regularly, but that you may have used during the days leading up to the radiological examination.</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">It is particularly important that you inform your doctor if you are taking any of the following medications:</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Biguanides</strong> (Metformin, a medication used to treat diabetes mellitus): If you suffer from acute kidney failure or severe, chronic kidney disease, there may be a delay in eliminating biguanides, which then accumulates in the blood and may result in lactic acidosis (too much acid in the blood).</p><p style="margin-left:0in; margin-right:0in; text-indent:0in"><strong>&nbsp;</strong></p><p style="margin-left:0in; margin-right:0in; text-indent:0in">Because the use of Ultravist-370 may cause kidney problems or make existing kidney problems worse, you may be exposed to an increased risk of developing lactic acidosis.</p><p style="margin-left:17.85pt; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">This is particularly true if you already suffer from impaired kidney function (see section&nbsp;2, sub-section &quot;Intravascular applications&quot;; &quot;Kidney function disorders&quot;). Depending on the results of a kidney function test, the advisability of stopping Metformin treatment should be carefully considered.</p><p style="margin-left:17.85pt; margin-right:0in">&nbsp;</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Interleukin-2:</strong> Previous treatment (up to several weeks) with interleukin-2 (a cancer drug) has been linked to an increased risk for delayed onset of contrast media reactions in association with Ultravist-370 use.</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p><p style="margin-left:28.35pt; margin-right:0in; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>Radioisotopes: </strong>Following intravascular administration (application in blood vessels) iodine-containing contrast media can reduce the ability of thyroid tissue to absorb isotopes. As a consequence, the diagnosing and treatment of disturbed thyroid gland function with thyrostatic radioisotopes may be impaired for several weeks after using Ultravist-370, and even longer in isolated cases.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>Pregnancy and breast-feeding</strong></p><p style="text-align:left">&nbsp;</p><p style="text-align:left">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left"><u>Pregnancy</u></p><p style="text-align:left">No well controlled studies have been conducted in pregnant women. Therefore, the safety of using Ultravist-370 during human pregnancy has not been sufficiently proven. Animal studies with iopromide did not show any evidence of a damaging effect during pregnancy as regards the development of the embryo/foetus, birth, or development of newborns after the use of iopromide for diagnostic purposes in humans.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">An X-ray examination exposes both the mother and the unborn baby to radiation. Because exposure to radiation should generally be avoided during pregnancy as far as possible, your physician needs to carefully assess the possible risks associated with radiological examinations, whether with or without contrast medium. In addition to the necessity of protecting the unborn baby from radiation, whenever iodine-containing contrast media are used the sensitivity of the foetal thyroid gland to iodine must also be considered.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left"><u>Breast-feeding</u></p><p style="text-align:left">The safety of Ultravist-370 in breast-fed infants has not been studied. It is not expected that small quantities of the active ingredient in Ultravist-370 might damage a breast-feeding infant, since only small quantities of the active ingredient in Ultravist-370 pass into breast milk (also see sections &quot;Warnings and precautions&quot;; &quot;Thyroid function disturbances&quot;. To avoid any possible overexposure to iodide by the breastfeeding baby (risk of blocking thyroid hormone synthesis), for safety reasons it is thus recommended that breastfeeding be suspended for 2&nbsp;days for babies of less than 4&nbsp;months of age, and that any siphoned milk be discarded.</p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>Driving and using machines</strong></p><p style="text-align:left">&nbsp;</p><p style="text-align:left">No studies on the effects on the ability to drive and use machines after use of Ultravist have been performed.</p><p style="text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>Ultravist-370 contains sodium</strong></p><p style="text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose (based on the average amount for a person weighing 70&nbsp;kg), that is to say essentially &lsquo;sodium-free&rsquo;.</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:0in; text-align:left">Ultravist-370 is injected or infused into a blood vessel (intravascular injection or infusion) or introduced into body cavities (intracavitary use).</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">Ultravist-370 will be given to you by a doctor or a trained healthcare professional.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">In case of intravascular administration (administration into a blood vessel) of Ultravist-370, your doctor will examine you for any underlying diseases, will ask you about any medicines you are taking/using, as these may possibly cause thromboembolic events to occur (blocking of a vessel by a blood clot).</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">Adequate fluid intake should be ensured before and after using Ultravist-370.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">Your doctor will</p><p style="margin-left:28.35pt; text-align:left; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->be particularly careful in carrying out the procedure to examine your blood vessels (angiography),</p><p style="margin-left:28.35pt; text-align:left; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->frequently rinse the catheter with saline solution (and using heparin if possible &ndash; a blood thinning drug),</p><p style="margin-left:28.35pt; text-align:left; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->keep the examination as short as possible to minimise the risk of developing an examination-related blood clot in blood vessels (thrombosis) or congestion (narrowing or blockage) of the vascular lumen by an embolus, e.g. a blood clot (embolism).</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">Your doctor will determine the correct dose of contrast medium for the radiological examination. If you&#39;re interested, ask him/her to explain the examination to you.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>How Ultravist-370 is dosed</strong></p><p style="margin-left:0in"><strong>&nbsp;</strong></p><p style="margin-left:0in"><strong>General information</strong></p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">The dose is determined on the basis of age, weight, heart and kidney functions, general health status, the specific clinical question, examination method and examined body region.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">The treating physician will determine the suitable iodine concentration and required volume for each individual patient. An overview of the recommended volumes for the various concentrations of iopromide solutions for each body region to be visualised is provided in the form of a table at the end of this leaflet.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">The total dose of 1.5&nbsp;g iodine per kg of body weight (equivalent to about 4&nbsp;mL&nbsp;Ultravist-370 per kg&nbsp;body weight) should not be exceeded on any given examination day.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Ultravist-370&nbsp;should be warmed to body temperature before being applied, which improves tolerability and makes it easier to inject because of the lower viscosity.</p><p style="margin-left:0in"><strong>&nbsp;</strong></p><p style="margin-left:0in"><strong>The following instructions pertain to the different types of use</strong></p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">Unless prescribed otherwise, the following dosage guidelines apply for the specific areas of use:</p><p style="text-align:left">&nbsp;</p><p style="text-align:left"><em>Imaging of the kidneys and urinary tract (intravenous urography)</em></p><p style="margin-left:0in; text-align:left">It is important to note that when conducting intravenous urography, relatively high doses of contrast medium are required for infants, because of the poor physiological concentrating ability of the immature nephron of the infantile kidney.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in"><em>Computerised tomography (CT)</em></p><p style="margin-left:0in">Ultravist-370&nbsp;should be administered as a rapid intravenous injection, and if possible, with the aid of a high pressure injector. When slow scanners are used, in order to achieve relatively constant blood levels we recommend that half of the dose be administered as a bolus and the remainder of the dose within 2&nbsp;-&nbsp;6&nbsp;minutes, even if a steady peak cannot be maintained. The scan process is started upon completion of the initial administration phase.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">When performing spiral CT, and in particular multi-slice techniques, a variety of data are compiled with the patient holding his/her breath. In order to optimise the effect of the intravenous bolus injection in the region of interest (optimal enhancement is achieved at different times in the pathologically changed tissues), the use of an automatic high-pressure injector and bolus is recommended.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">When performing CT, the required quantity of contrast media and administration rate are determined relative to the organs to be examined, the diagnostic question at hand, but also in consideration of the apparatus actually available for the specific examination (e.g. scan and image forming times). Infusion is recommended when using slow-working devices, and bolus injection for fast scanners.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left"><em>Digital subtraction angiography (DSA)</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">In many cases, intra-arterial DSA can yield strongly enhanced images of the great vessels and arteries of the neck, kidney and limbs, even in cases where the applied concentration of Ultravist-370 is insufficient for conventional angiography. This method is thus recommended for patients with impaired renal function.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left"><em>Visualization of body cavities</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">When performing arthrography, hysterosalpingography or ERCP, the contrast medium should be injected under fluoroscopic monitoring.</p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>Additional information for certain patient populations</strong></p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left"><em>Newborns and infants</em></p><p style="margin-left:0in">Infants under 1&nbsp;year of age, in particular newborns, are vulnerable to electrolyte balance disturbances and changes in blood circulation (haemodynamic changes). The doctor will carefully select the dose of contrast medium and conduct the radiological examination in such a way so as to take the patient&#39;s actual status into account.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left"><em>Patients with impaired kidney function</em></p><p style="margin-left:0in">Because iopromide, the active ingredient in Ultravist-370, is almost always excreted via the kidneys in unchanged form, the time required to eliminate iopromide is longer in patients with kidney failure. The dose of contrast medium for patients with pre-existing impaired kidney function should be kept as low as possible in order to reduce the risk of any contrast-medium-induced kidney injury (also see section &quot;Warnings and precautions&quot;).</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">For more information on the use and handling of Ultravist-370, see the instructions provided at the end of this leaflet (see section &quot;The following information is intended for doctors and qualified medical staff only&quot;).</p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>Notes on practical use</strong></p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Ultravist-370 is supplied as a ready-to-use, clear, colourless to pale yellow solution. The contrast medium must be inspected visually prior to use. Because Ultravist-370 is a highly concentrated solution, crystallization may occur in rare cases (milky-turbid appearance and/or bottom sediment or swimming crystals). It is prohibited to use a contrast medium if it is severely discoloured, if particles (incl. crystals) are visible, or if the container is damaged.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">The contrast medium solution must be drawn up into the syringe or the container attached to the infusion device just prior to conducting the examination.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">To prevent significant quantities of micro-particles from entering the solution via the stopper the rubber stopper may only be pierced once. A long-tip cannula with a maximum diameter of 18&nbsp;G is recommended for piercing the stopper and for drawing up the contrast medium (special withdrawal cannulas with a side hole are particularly suitable).</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Contrast media solutions as solutions for injection are packaged for one-time use only. Any contrast media remaining after the examination procedure must discarded and disposed of appropriately.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Whenever an automatic application system is used to administer a medicinal product, the medicinal product manufacturer must provide evidence of the suitability of any such planned use, as well as the sterility of the contrast medium. The instructions for use of the medicinal product in question must be strictly followed. It is prohibited to use automatic application systems in babies and small children.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">The following supplemental rules apply when using prefilled plastic cartridges: only qualified medical staff are allowed to administer contrast media and the procedure must always be conducted using the appropriate methods and apparatus. Sterile handling techniques must be strictly followed for all injections involving contrast media. The contrast media must be administered with a suitable injector. The type of injector required is clearly marked on the container itself. Any pertinent manufacturer instructions must be strictly followed.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>If you are given more Ultravist-370 than planned</strong></p><p style="text-align:left">&nbsp;</p><p style="text-align:left">Inform your doctor immediately if you are given more Ultravist-370 than is required and you do not feel well.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">An overdose can affect the pulmonary and cardiovascular system, which can cause undesired effects and even life-threatening reactions. Symptoms of an overdose include an imbalance of bodily fluids and electrolytes, kidney failure, cardiovascular (heart and blood vessels) and respiratory (pertaining to breathing functions) complications.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">For this reason, treatment for an overdose consists of maintaining all life-preserving functions and carefully initiating therapy for the specific symptoms. In the event of an accidental overdose your water/electrolyte imbalance and kidney function must be monitored. Your doctor may decide to perform dialysis to remove Ultravist-370 from your body.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">If you have any further questions about this medicine, ask your doctor.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left">Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">Please tell your doctor or pharmacist if you notice any side effects or suspect that any complaints you may have are connected with the administration of this X-ray contrast medium. This also applies if the complaints are not listed as a side effect in this leaflet. Note that side effects can also occur after some delay &ndash; possibly much later after the X-ray examination.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">The most frequently occurring side effects observed in patients after using Ultravist-370 (&ge;4%) are headache, nausea and dilated blood vessels (vasodilation).</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">The most serious side effects observed in patients after using Ultravist-370 are shock, anaphylactoid shock, respiratory arrest, difficulty in breathing (bronchospasm), swelling of the larynx (laryngeal oedema), swelling in the pharynx (pharyngeal oedema), asthma, coma, reduced blood supply to the brain (cerebral ischaemia/cerebral infarction), stroke, swelling of the brain (cerebral oedema), cerebral seizures/convulsion, irregular heartbeat (arrhythmia), cardiac arrest, chest pain resulting from reduced oxygen supply to the heart (myocardial ischaemia), heart attack (myocardial infarction), heart failure, slower heart rate (bradycardia), bluish colour of skin and mucosa due to lack of oxygen (cyanosis), low blood pressure, breathlessness (dyspnoea), accumulation of fluid in the lungs (pulmonary oedema) and shortness of breath (respiratory insufficiency).</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="text-align:left">Different kinds of side effects may occur in association with the use of contrast media containing iodine. We differentiate between unpredictable pseudo-allergic reactions (also see section &ldquo;Warnings and precautions&rdquo;, hypersensitivity reactions in the form of allergoid and anaphylactoid or pseudo-allergic reactions, as well as pharmacologically explainable and predictable organotoxic reactions. Pseudo-allergic and organotoxic reactions can also occur simultaneously, and it is not always possible to definitively categorise the specific event.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>Common:</strong> Can affect up to 1 in 10 patients treated</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taste disorders (dysgeusia)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blurred vision/visual impairment</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain/feeling of tightness in chest</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood pressure (hypertension)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dilated blood vessels (vasodilation)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pains</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reaction at injection site of various types: e.g. pain, sensation of heat<sup>&sect;)</sup>, swelling<sup>&sect;)</sup> (oedema), inflammation<sup>&sect;)</sup> and injury to surrounding soft tissues<sup>&sect;) </sup>if Ultravist-370 is discharged from the injection site)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flushing</p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>Uncommon:</strong> Can affect up to 1 in 100 patients treated</p><p style="margin-left:0in; margin-right:0in; text-align:left">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity/allergy-like (anaphylactoid) reactions:</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left">anaphylactoid shock<sup>&sect;)*)</sup>, respiratory arrest<sup>&sect;)*)</sup>, cramping of bronchial musculature<sup>*)</sup> (bronchospasm), swelling of the larynx region<sup>*) </sup>(laryngeal oedema)/swelling of the pharynx<sup>*) </sup>(pharyngeal oedema)/swelling in the face (facial oedema), (swelling of the tongue<sup>&sect;)</sup> (tongue oedema), laryngospasm (cramping in the area of the larynx/cramping in the area of the pharynx<sup>&sect;)</sup> (laryngospasm/pharyngeal spasm), asthma<sup>&sect;)*)</sup>, inflammation of the conjunctiva<sup>&sect;)</sup> (conjunctivitis), lacrimation<sup>&sect;)</sup>, sneezing, coughing, swelling of the mucosa (mucosal oedema), inflammation of the nasal lining<sup>&sect;)</sup> (rhinitis), hoarseness<sup>&sect;)</sup>, throat irritation<sup>&sect;)</sup>, hives (urticaria), itchiness (pruritus), swelling of the skin and mucosa (angioedema)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unconsciousness/fainting, drop in blood pressure with related drop in heart rate (vasovagal reactions)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disorientation</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Restlessness</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unusual skin sensitivity such as burning, tingling, itching or prickling (paraesthesia)/limited sense of touch or skin sensation (hypaesthesia)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced alertness/drowsiness (somnolence)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disturbed heart rhythm<sup>*)</sup> (arrhythmia)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure<sup>*)</sup> (hypotension)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath<sup>*)</sup> (dyspnoea)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach ache (abdominal pain)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swollen tissues (oedema)</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>Rare: </strong>Can affect up to 1 in 1,000 patients treated</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety attacks</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiac arrest<sup>*)</sup></p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain due to reduced oxygen supply to the heart<sup>*)</sup> (myocardial ischaemia)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Palpitations</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">&nbsp;</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt"><strong>Not known: cannot be estimated from the available data</strong></p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Episodes of life-threatening hyperfunctioning of the thyroid gland (thyrotoxic crisis)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thyroid function disturbances</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Coma<sup>*)</sup></p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced blood supply in the brain<sup>*) </sup>(cerebral ischaemia/cerebral infarction)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stroke<sup>*)</sup></p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the brain<sup>a)*) </sup>(cerebral oedema)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cerebral seizures/convulsions<sup>a)*)</sup></p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Temporary impaired vision<sup>a)</sup> (cortical blindness)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unconsciousness</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excitation and restlessness (agitation)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Memory loss (amnesia)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trembling (tremor)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Speech disorders</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Partial/complete body paralysis (paresis/paralysis)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hearing disturbances</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart attack<sup>*)</sup> (myocardial infarction)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart failure<sup>*)</sup></p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slower heartbeat<sup>*) </sup>(bradycardia)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Faster heartbeat (tachycardia)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bluish colour of skin and mucosa due to lack of oxygen<sup>*) </sup>(cyanosis)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shock<sup>*)</sup></p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blocking of a vessel by blood clots<sup>a)</sup> (thromboembolic events)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden cramp-like constriction of a blood-carrying vessel<sup>a)</sup> (vasospasm)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluid accumulation in the lungs<sup>*) </sup>(pulmonary oedema)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath<sup>*) </sup>(respiratory insufficiency)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallowing disorders (dysphagia)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the salivary gland</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loose bowels (diarrhoea)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diseases of the skin with blister formation (e.g. Stevens-Johnson or Lyell&#39;s syndrome)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash (exanthema)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reddening of the skin (erythema)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive sweating (hyperhidrosis)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pressure in muscle tissue leading to damaged muscle and nerve tissues, in addition to blood flow disorders<sup>a)</sup> (Compartment syndrome following extravasation)</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney function disorders<sup>a)</sup></p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute kidney failure<sup>a)</sup></p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Malaise</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chills</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paleness</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in body temperature</p><p style="margin-left:0in; margin-right:0in; text-align:left"><sup>&nbsp;</sup></p><p style="margin-left:0in; margin-right:0in; text-align:left"><em><sup>*)</sup></em><em> life-threatening and/or cases involving death have been reported</em></p><p style="margin-left:0in; margin-right:0in; text-align:left"><em><sup>a)</sup></em><em> applies only for intravascular application</em></p><p style="margin-left:0in; margin-right:0in; text-align:left"><em><sup>&sect;)</sup></em><em> observed only after market launch (unknown frequency of occurrence)</em></p><p style="text-align:left"><strong><em>&nbsp;</em></strong></p><p style="margin-left:0in; margin-right:0in; text-align:left">Seek medical attention immediately if you notice any of the following signs and symptoms (whose frequency is not known):</p><p style="margin-left:.25in; margin-right:0in; text-align:left; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Reddish patches on the trunk, the patches are target-like macules or circular, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes. These serious skin rashes can be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome, toxic epidermal necrolysis).</p><p style="margin-left:.25in; margin-right:0in; text-align:left; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Widespread rash, high body temperature and enlarged lymph nodes (DRESS syndrome or drug hypersensitivity syndrome).</p><p style="margin-left:.25in; margin-right:0in; text-align:left; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->A red, scaly widespread rash with bumps under the skin and blisters accompanied by fever after the imaging procedure (acute generalised exanthematous pustulosis).</p><p style="margin-left:.25in; margin-right:0in; text-align:left; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Short term brain disorder (encephalopathy) which can cause memory loss, confusion, hallucinations, difficulties with vision, loss of vision, seizures, loss of coordination, loss of movement in one side of the body, problems with speech, and loss of consciousness.</p><p style="text-align:left"><strong>&nbsp;</strong></p><p style="text-align:left"><strong>Intravascular use (</strong><strong>administration into a blood vessel)</strong></p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Side effects associated with the intravascular administration of iodinated contrast media are usually mild to moderate and temporary in nature. Nevertheless, serious and rare life-threatening reactions can occur that require rapid and effective emergency treatment.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Reactions to contrast media occur much more frequently and are more severe after intravascular administration, than when they are introduced into body cavities (intra-ductal and intracavitary administration).</p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong><em>&nbsp;</em></strong></p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>Use in body cavities</strong></p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Since small quantities of contrast media can also pass into the blood vessel after placing the contrast medium into body cavities (intra-ductal, intracavitary administration), when this administration method is used, allergy-like reactions can occur such those also described for contrast medium administration into blood vessels.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">When visualising body cavities, symptoms tend occur as a function of the examined region, and in most cases, are caused by the chosen examination techniques. Most adverse events occurring after use in body cavities occur within one hour after the examination.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Pain due to expansion may be experienced when filling body cavities with contrast media.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">In addition to the side effects mentioned above, after <strong>ERCP examinations, a</strong> temporary (reversible) increase in pancreas enzymes (amylase and lipase) and onset of pancreatitis (inflammation of the pancreas) have also been reported, including necrotising (dying tissues) pancreatitis. The frequency of occurrence of these side effects is unknown. The reason for this may be increased pressure in the small pancreatic ducts, due to an excess quantity of contrast medium being injected.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">Uncommon cases of gastrointestinal problems have been reported after swallowing contrast media.</p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>Reporting of side effects</strong></p><p style="margin-left:0in; margin-right:0in; text-align:left">If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in"><strong>To report any side effect(s):</strong></p><p style="margin-left:0in; margin-right:0in">The National Pharmacovigilance Centre (NPC).</p><p style="margin-left:0in; margin-right:0in">Fax: + 966 - 11 - 205 - 7662.</p><p style="margin-left:0in; margin-right:0in">SFDA call center: 19999.</p><p style="margin-left:0in; margin-right:0in">E - mail: npc.drug@sfda.gov.sa.</p><p style="margin-left:0in; margin-right:0in; text-align:left">Website: https://ade.sfda.gov.sa</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:0in; text-align:left">Keep this medicine out of the sight and reach of children.</p><p style="margin-left:0in; text-align:left">Do not use this medicine after the expiry date which is stated on the container/carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left"><strong>Storage conditions</strong></p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">Protect from light and X-rays.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">Do not store above 30&deg;C.</p><p style="text-align:left">&nbsp;</p><p style="text-align:left">It is prohibited to use contrast media that are severely discoloured, that contain particles, or if the container is damaged.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">This medicinal product is meant for one-time use only.</p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>Note about shelf-life after opening</strong></p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">The chemical and physical stability of the ready-to-use preparation (solution for injection or infusion) has been demonstrated at 36-38&ordm;&nbsp;Celsius for a period of 10&nbsp;hours. From a microbiological point of view, the ready-to-use preparation should be used immediately, unless the method used to open the container ensures that there is no risk of contamination.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">If the ready-to-use preparation is not administered immediately, the operator must ensure that the remaining solution is used within the allotted time period and under the appropriate conditions.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">Never throw away any medicines via wastewater (e.g. down the toilet or sink). Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p style="margin-left:0in">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:left"><strong>What Ultravist-370 contains</strong></p><p style="text-align:left">&nbsp;</p><p style="margin-left:28.35pt; margin-right:0in; text-align:left; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The active substance is iopromide. 1&nbsp;mL solution for injection or infusion contains 769&nbsp;mg iopromide (equivalent to 370&nbsp;mg bound iodine/mL).</p><p style="text-align:left">&nbsp;</p><table cellspacing="0" cellpadding="0" border="1" style="width:558px"><tbody><tr><td colspan="2" style="vertical-align:top; width:418.15pt"><p style="margin-left:3.7pt; margin-right:0in">Content and concentration of the active substance in Ultravist-370&nbsp;and resulting content and concentration values of bound iodine</p></td></tr><tr><td style="vertical-align:top; width:283.5pt"><p style="margin-left:3.7pt; margin-right:0in"><strong>Iopromide </strong>concentration (mg/mL)</p></td><td style="vertical-align:top; width:134.65pt"><p style="margin-left:3.7pt; margin-right:0in">769</p></td></tr><tr><td style="vertical-align:top; width:283.5pt"><p style="margin-left:3.7pt; margin-right:0in">Iopromide content (g) in</p><p style="margin-left:3.7pt; margin-right:10.65pt">&nbsp;</p><p style="margin-left:3.7pt; margin-right:10.65pt">Bottle containing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50&nbsp;mL</p><p style="margin-left:3.7pt; margin-right:10.65pt">Bottle containing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 100&nbsp;mL</p></td><td style="vertical-align:top; width:134.65pt"><p style="margin-left:3.7pt; margin-right:0in">&nbsp;</p><p style="margin-left:3.7pt; margin-right:60.25pt; text-align:left">&nbsp;</p><p style="margin-left:3.7pt; margin-right:82.25pt">38.4</p><p style="margin-left:3.7pt; margin-right:82.25pt">76.9</p></td></tr><tr><td style="height:4.1pt; vertical-align:top; width:283.5pt"><p style="margin-left:.05in; margin-right:0in"><strong>Iodine</strong> concentration (mg/mL)</p></td><td style="height:4.1pt; vertical-align:top; width:134.65pt"><p style="margin-left:.05in; margin-right:0in">370</p></td></tr><tr><td style="height:58.4pt; vertical-align:top; width:283.5pt"><p style="margin-left:.05in; margin-right:10.75pt"><strong>Iodine </strong>content per container (g) for</p><p style="margin-left:.05in; margin-right:.05in">&nbsp;</p><p style="margin-left:.05in; margin-right:.05in">Bottle containing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50&nbsp;mL</p><p style="margin-left:.05in; margin-right:.05in">Bottle containing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 100&nbsp;mL</p></td><td style="height:58.4pt; vertical-align:top; width:134.65pt"><p style="margin-left:.05in; margin-right:0in">&nbsp;</p><p style="margin-left:.05in; margin-right:82.25pt">&nbsp;</p><p style="margin-left:.05in; margin-right:82.25pt">18.5</p><p style="margin-left:.05in; margin-right:82.25pt">37.0</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:28.35pt; text-align:left; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The other ingredients are: sodium calcium edetate, hydrochloric acid (to adjust pH), trometamol and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Ultravist-370 is a clear, colourless to pale yellowish, particle-free solution for injection or infusion.

Physico-chemical and physical properties of Ultravist-370:
Property (unit of measurement)	Value
pH	6.5 - 8.0
Viscosity (mPa·s / cP)	
	at 20°C	22.0

	at 37°C	10.0
Osmotic pressure at 37°C	
		(MPa)	2.02
		(atm)	19.9
Osmolality at 37°C (Osm/kg H2O)	0.77
Osmolarity at 37°C (Osm/l sol.)	0.49
Density (g/mL)	
at 20°C	1.409
at 37°C	1.399
Molecular weight of iopromide (g/mol)	791.12

Ultravist-370 is available in the following pack sizes:
10 bottles, each containing 50 or 100 mL

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:0in; margin-right:0in; text-align:left"><strong>Manufacturer</strong></p><p style="margin-left:0in; margin-right:0in; text-align:left">Bayer AG, Mullerstrasse 178,</p><p style="margin-left:0in; margin-right:0in; text-align:left">13353 Berlin, Germany.</p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>Marketing authorisation holder:</strong></p><p style="margin-left:0in; margin-right:0in">Bayer AG, 51368 Leverkusen, Germany.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in July 2021.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">يُعد اولترافيست-370 وسيطًا تباينيًا يحتوي على اليود أحادي الجزيء وغير أيوني للأشعة السينية.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">ويمتص اليود الأشعة السينية، مما يسهل رؤية مناطق الجسم التي يوجد بها اولترافيست-370.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">سيعطيك أخصائيو الرعاية الصحية المدربون الوسيط التبايني.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">يُستخدم اولترافيست-370 للأغراض التالية:</p><p dir="RTL" style="margin-left:0in; text-align:right; text-indent:0in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تصوير الأوعية الدموية بالأشعة السينية (تصوير الأوعية الدموية شعاعيًا، تصوير الأوعية الدموية بالطرح الرقمي داخل الشرايين)</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right; text-indent:0in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تعزيز تباين التصوير المقطعي المحوسب (CT)</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right; text-indent:0in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تصوير الكلى والمسالك البولية السفلية (تصوير الجهاز البولي)</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right; text-indent:0in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تصوير تجاويف الجسم (باستثناء: تصوير النخاع، تصوير البطينات، تصوير الصهاريج).</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">يُستخدم اولترافيست-370 لأغراض تشخيصية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">لغرض الحد من مخاطر حدوث أي حالات عدم توافق محتملة، لن يخلط طبيبك/أخصائي الرعاية الصحية المدربين اولترافيست-370 مع أي أدوية أخرى.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>موانع استخدام اولترافيست-370</strong></p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه أيوبرومايد أو اليود أو أي من المواد الأخرى المستخدمة في تركيبة هذا المنتج الدوائي (الوارد ذكرها في القسم 6).</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">تحدث مع طبيبك، أو الممرض قبل استخدام اولترافيست-370:</p><p dir="RTL" style="margin-right:.25in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت تُعاني من طفح جلدي حاد أو تقشر جلدي أو بثور وتقرحات في الفم أو أيًا منهما بعد استخدام اولترافيست-370.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><u>&nbsp;</u></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><u>لجميع أنواع الاستخدامات</u></p><p dir="RTL" style="text-align:right"><em>تفاعلات فرط الحساسية (تفاعلات شبيهة بالحساسية أو تفاعلات تأقية)</em></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">يُرجى إبلاغ طبيبك عند معاناتك من إحدى الحالات التالية:</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك رد فعل تجاه وسيط تبايني آخر في الماضي،</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت من الربو أو الحساسية أو تعاني منها حاليًا,</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">حيث يعني ذلك أنك تُعاني من خطر متزايد للإصابة برد فعل شبيه بالحساسية تجاه اولترافيست-370 (متضمنًا ردود الفعل الحادة). وسيُقرر طبيبك بعد ذلك ما إذا كان يجب إجراء الفحص المخطط أم لا.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">بعد استخدام اولترافيست-370، قد تحدث ردود فعل شبيهة بالحساسية تعتمد على الجرعة بدرجات متفاوتة من الشدة (الحساسية) أو حتى صدمة أو أعراض أخرى مختلفة، على سبيل المثال في شكل ردود فعل تصيب القلب الوعائي (القلب والأوعية الدموية) والجهاز التنفسي (الممرات الهوائية) والجلد.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">لأن مثل هذه الحالات تحدث بشكل غير منتظم، فلا يُمكن التنبؤ بها في الحالات الفردية. وتحدث معظم ردود الفعل خلال نصف ساعة من تناول وسيط التباين، إلا أن ردود الفعل قد تحدث أيضًا في وقت لاحق (بعد ساعات أو أيام).</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">ينبغي إبلاغ طبيبك إذا كنت تتناول معوقات بيتا، أي الأدوية التي تُستخدم لعلاج ارتفاع ضغط الدم. وقد لا يستجيب المرضى الذين يتناولون معوقات بيتا للعلاج القياسي بمضادات بيتا (يُرجى الاطلاع على القسم الفرعي &quot;الأدوية الأخرى واولترافيست-370&quot; في هذا القسم).</p><p dir="RTL" style="text-align:right">قد يعطيك طبيبك مركبات الكورتيكوستيرويد قبل الفحص إذا كان تعاني من خطر متزايد للإصابة برد فعل حاد شبيه بالحساسية (على سبيل المثال إذا كان لديك بالفعل رد فعل معتدل الحدة أو حاد وإذا كنت تعاني من الربو أو الحساسية التي تتطلب العلاج).</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">كما ينبغي إبلاغ طبيبك إذا كنت تعاني من أي أمراض في الجهاز القلبي الوعائي. وفي حالة حدوث تفاعل حاد لفرط الحساسية، فتزداد احتمالية خطر حدوث عواقب وخيمة أو حتى مميتة.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><em>الاستعداد لحالة طوارئ</em></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">بغض النظر عن معدل الاستخدام ونوعه، قد تكون أعراض الحساسية الطفيفة أول علامة على حدوث رد فعل تأقاني حاد يتطلب العلاج. وهذا هو السبب في عدم إعطاء وسائط التباين التي تحتوي على اليود إلا في المرافق التي يتوفر فيها علاج حالات الطوارئ، أي المعدات والأدوية المناسبة والطاقم الطبي والمساعدين الطبيين المدربين تدريباً مناسباً.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">لذلك، ينبغي أن تكون التدابير الاحترازية الدقيقة لعلاج ردود الفعل الخطيرة على الفور متاحة دائمًا لجميع المرضى، بالإضافة إلى أدوية الطوارئ الضرورية وأدواتها.</p><p dir="RTL" style="text-align:right">بعد تلقيك محلول اولترافيست-370، سيراقب طبيبك حالتك عن كثب لمدة لا تقل عن نصف ساعة، حيث تُظهر التجربة أن الأحداث الأكثر خطورة تحدث خلال هذه الفترة الزمنية.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><em>ردود فعل جلدية خطيرة</em></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">يُرجى توخي الحذر عند استخدام اولترافيست-370:</p><p dir="RTL" style="text-align:right">جرى الإبلاغ عن ردود فعل جلدية خطيرة متضمنة متلازمة ستيفنز جونسون (SJS) وتقشر الأنسجة المتموتة البشروية التسممي (TEN)، ورد الفعل الدوائي مع كثرة اليوزينيات والأعراض الجهازية (DRESS) والبثور الطارئة الحادة المعممة (AGEP) بالاشتراك مع استخدام اولترافيست-370. ويُرجى طلب العناية الطبية فورًا إذا لاحظت أيًا من العلامات الموضحة في القسم 4.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><em>اضطرابات وظائف الغدة الدرقية</em></p><p dir="RTL" style="margin-left:0in; text-align:right; text-indent:0in">تؤثر وسائط تباين الأشعة السينية التي تحتوي على اليود على وظيفة الغدة الدرقية عبر اليوديد الحر الموجود في المحاليل واليوديد الذي يُطلق لاحقًا في الجسم بسبب إزالة اليود بعد تلقي وسيط التباين.</p><p dir="RTL" style="margin-left:0in; text-align:right; text-indent:0in">يُرجى إبلاغ طبيبك إذا كنت تعاني من فرط نشاط الغدة الدرقية أو عند ظنك بأنك تعاني من فرط نشاط الغدة الدرقية أو إذا كنت تعاني من تضخم الغدة الدرقية العقدي. وفي مثل هذه الحالات، قد تؤدي وسائط التباين التي تحتوي على اليود إلى فرط نشاط الغدة الدرقية أو حتى أزمة تسمم درقي (مضاعفات حادة مرتبطة بالغدة الدرقية شديدة النشاط).</p><p dir="RTL" style="margin-left:0in; text-align:right; text-indent:0in">يُرجى إبلاغ طبيبك إذا كان لديك تاريخ طبي لاضطراب الغدة الدرقية، متضمنًا قصور الغدة الدرقية (خمول الغدة الدرقية)؛ حيث توجد تقارير عن قيم دم غير طبيعية في اختبارات وظائف الغدة الدرقية بعد استخدام وسائط التباين التي تحتوي على اليود. وقد يشير ذلك إلى قصور نشاط الغدة الدرقية أو ضعف عابر (مؤقت) في وظيفة الغدة الدرقية.</p><p dir="RTL" style="margin-left:0in; text-align:right; text-indent:0in">إذا خُطط لاستخدام وسائط التباين التي تحتوي على اليود لمريض لديه مثل هذه المخاطر، فيجب فحص وظيفة الغدة الدرقية للمريض قبل تلقي اولترافيست-370 ويجب البدء في العلاج الدرقي إذا لزم الأمر.</p><p dir="RTL" style="margin-left:0in; text-align:right; text-indent:0in">&nbsp;</p><p dir="RTL" style="margin-left:0in; text-align:justify"><em>ضعف الغدة الدرقية لدى الأطفال من عمر 0 إلى 3 سنوات</em></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:justify">تم الإبلاغ عن اختلال وظيفي في الغدة الدرقية يتميز بقصور نشاط الغدة الدرقية أو تثبيط عابر للغدة الدرقية بعد التعرض الفردي والتعرض المتعدد لوسائط التباين المعالجة باليود. بين المرضى الذين تتراوح أعمارهم بين 0 و 3 سنوات والذين تعرضوا لوسائط تباين معالج باليود ، تم الإبلاغ عن اختلال وظيفي في الغدة الدرقية بنسبة 1٪ إلى 15٪ اعتمادًا على عمر المريض وجرعة عامل التباين المعالج باليود.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:justify">يرتبط العمر الأصغر، والوزن المنخفض جدًا عند الولادة، والولادة المبكرة، ووجود حالات أخرى، مثل الدخول إلى وحدات العناية المركزة للأطفال حديثي الولادة أو الأطفال ، وحالات القلب بزيادة المخاطر. قد يكون مرضى الأطفال المصابون بأمراض قلبية في خطر أكبر نظرًا لأنهم يحتاجون غالبًا إلى جرعات عالية من التباين أثناء إجراءات القلب الغازية ، مثل القسطرة والتصوير المقطعي المحوسب (CT)</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">يحتاج مرضى الأطفال الذين تتراوح أعمارهم بين 0 و 3 سنوات إلى مراقبة عن كثب لأن الغدة الدرقية غير النشطة أثناء الحياة المبكرة قد تكون ضارة للحركة والسمع والنمو المعرفي وقد تتطلب علاجًا مؤقتًا ببدائل T4. تقييم وظيفة الغدة الدرقية لدى جميع مرضى الأطفال من سن 0 إلى 3 سنوات في غضون 3 أسابيع بعد التعرض لوسائط التباين المعالجة باليود ، خاصة عند حديثي الولادة الناضجين أو المبتسرين. إذا تم الكشف عن وجود خلل وظيفي في الغدة الدرقية ، فقم بعلاج ومراقبة وظيفة الغدة الدرقية حسب الحاجة السريرية.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><em>اضطرابات الجهاز العصبي</em></p><p dir="RTL" style="text-align:right">قد تواجه اضطرابًا دماغيًا قصير المدى يُسمى اعتلال الدماغ أثناء إجراء التصوير أو بعده بفترة قصيرة. ويُرجى إخبار طبيبك على الفور إذا لاحظت أيًا من العلامات والأعراض المرتبطة بهذه الحالة الموضحة في القسم 4.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">يُرجى إبلاغ طبيبك إذا كنت تعاني من أي اضطرابات في الجهاز العصبي المركزي (CNS)، مثل النوبات. وفيما يتعلق باستخدام اولترافيست -300، قد تكون أكثر عرضة للإصابة بمضاعفات عصبية؛ حيث تحدث هذه المضاعفات بشكل متكرر أثناء تصوير الأوعية الدماغية (فحوصات الأشعة السينية للأوعية الدموية في الدماغ) وغيرها من الفحوصات المماثلة.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">ينبغي توخي الحذر الشديد للمرضى الذين يعانون من عتبات نوبات منخفضة، على سبيل المثال بسبب النوبات السابقة والاستخدام المتزامن لبعض الأدوية.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">تعمل العوامل التي تزيد من نفاذية الحاجز الدموي الدماغي على تسهيل انتقال وسيط التباين إلى أنسجة الدماغ، مما قد يؤدي إلى حدوث مضاعفات عصبية.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><em>توازن السوائل في الجسم (الترطيب)</em></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">لا ينبغي لك تناول اولترافيست-370 إذا كنت تعاني من الجفاف (عدم كفاية السوائل في جسمك)؛ وتجنبًا لذلك، سيتأكد طبيبك من أنك استهلكت كمية كافية من السوائل قبل الفحص (يُرجى الاطلاع أيضًا على القسم 2 &quot;الاستخدامات داخل الأوعية الدموية (الحقن في الأوعية الدموية)&quot;).</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">ينطبق هذا تحديدًا على المرضى المعرضين لخطر متزايد لإصابة الكلى الحادة المرتبطة بوسط التباين (PC-AKI) (يُرجى الاطلاع على القسم 2 &quot;الاستخدامات داخل الأوعية الدموية - إصابة <em>الكلى الحادة </em>&quot;) وكذلك المرضى الذين يعانون من زيادة إفرازات البول (البوال) وانخفاض إفرازات البول (نقص البول) وحديثي الولادة والرضع والأطفال الصغار والمرضى الأكبر سنًا.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">أخبر طبيبك إذا كنت تعاني من ضعف في وظائف الكلى. وسيضمن طبيبك من تناولك كمية كافية من الماء قبل الفحص. وسيُراعى الترطيب الكافي بإعطاء محلول للحقن في الوريد، خاصةً للمرضى الذين يعانون من إصابة الكلى الحادة المرتبطة بوسط التباين (PC-AKI). وسيتخذ طبيبك القرار بناءً على توصيات الإرشادات السريرية الحالية ونسبة الفائدة إلى المخاطر الفردية. وستراعى شروط المراقبة وتُؤخذ في الاعتبار. ويُرجى إخبار طبيبك إذا كنت تعاني من المشاكل الكلوية الحادة المرتبط بأمراض القلب؛ وقد يؤدي الترطيب الوريدي (إعطاء محلول الحقن في الوريد) إلى مضاعفات خطيرة لدى المرضى الذين يعانون من أمراض القلب.</p><p dir="RTL" style="text-align:justify">&nbsp;</p><p dir="RTL" style="text-align:right"><em>القلق</em></p><p dir="RTL" style="text-align:right">إذا كنت تعاني من القلق، أخبر طبيبك قبل استخدام اولترافيست-370؛ فقد يؤدي الإفراط في الانفعال والقلق والألم إلى زيادة مخاطر الآثار الجانبية أو تكثيف ردود الفعل المرتبطة بالوسائط التباينية (يُرجى الاطلاع أيضًا على القسم 4 &quot;الآثار الجانبية المحتملة&quot;).</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><em>الاختبار المسبق</em></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">لا يُنصح بإجراء اختبار مسبق لفرط الحساسية باستخدام جرعة اختبار منخفضة من اولترافيست-370، نظرًا لأن هذا النهج ليس له قيمة تنبؤية، وقد أدى في بعض الأحيان إلى تفاعلات فرط حساسية خطيرة وأحيانًا مميتة.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><em><u>&nbsp;</u></em></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><u>الاستخدامات داخل الأوعية الدموية (الحقن في الأوعية الدموية)</u></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><em>أمراض القلب والأوعية الدموية</em></p><p dir="RTL" style="text-align:right">إذا حُقنت بمحلول اولترافيست-370 لغرض فحص الأوعية الدموية مع معاناتك من مرض خطير في الدورة الدموية أو مرض حاد في الأوعية التاجية (نقص الأكسجين في عضلة القلب، ألم في الصدر)، فإنك بذلك تواجه خطر متزايد في حدوث تغيرات ذات الصلة سريريًا في الدورة الدموية (تغيرات ديناميكية الدم) وعدم انتظام ضربات القلب (عدم انتظام ضربات القلب). (يُرجى الاطلاع أيضًا على القسم 3 &quot;كيفية تناول اولترافيست-370 - <em>المرضى الذين يعانون من اختلال وظائف الكلى</em>&quot;).</p><p dir="RTL" style="text-align:right">ينطبق هذا الأمر تحديدًا بعد حقن وسائط التباين في شرايين أو حجرات القلب (يُرجى الاطلاع على قسم &quot;الآثار الجانبية المحتملة&quot;).</p><p dir="RTL" style="text-align:right">يُعد المرضى المعرضون بشكل خاص لخطر ردود الفعل القلبية أولئك الذين يعانون من ضعف عضلة القلب (قصور القلب) ومرض القلب التاجي الحاد والذبحة الصدرية غير المستقرة وأمراض صمام القلب واحتشاء عضلة القلب والمجازة التاجية وارتفاع ضغط الرئة (ارتفاع ضغط الدم الرئوي). و إذا كنت تعاني من قصور في القلب، فقد يؤدي استخدام اولترافيست-370 إلى تراكم السوائل في الرئتين (الوذمة الرئوية).</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><em>إصابة الكلى الحادة</em></p><p dir="RTL" style="text-align:right">ثمة خطر يتمثل في إصابة الكلى (إصابة الكلى الحادة المرتبطة بالوسط المتباين/ PC-AKI) بعد حقن محلول اولترافيست-370 داخل الأوعية (الحقن في وعاء دموي)؛ وقد يؤدي إلى اضطراب مؤقت في وظائف الكلى؛ وقد يُسبب فشل كلوي عند بعض المرضى.</p><p dir="RTL" style="text-align:right">يتضمن التعريض ما يلي:</p><p dir="RTL" style="margin-left:0in; margin-right:.25in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->القصور الحالي في وظائف الكلى (القصور الكلوي)،</p><p dir="RTL" style="margin-left:0in; margin-right:.25in; text-align:right">يُمكنك الاطلاع على المزيد من المعلومات في القسم 3 &quot;كيفية تناول اولترافيست-370 - <em>المرضى الذين يعانون من اختلال وظائف الكلى</em>&quot;،</p><p dir="RTL" style="margin-left:0in; margin-right:.25in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الجفاف،</p><p dir="RTL" style="margin-left:0in; margin-right:.25in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الداء السكري،</p><p dir="RTL" style="margin-left:0in; margin-right:.25in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->سرطان خلايا بلازما نخاع العظام (الورم النقوي المتعدد) /</p><p dir="RTL" style="margin-left:0in; margin-right:.25in; text-align:right">زيادة عدد البروتينات في الدم (بروتينات الدم)،</p><p dir="RTL" style="margin-left:0in; margin-right:.25in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->جرعات عالية من وسائط التباين والحقن المتعدد لمحلول اولترافيست-370 أو أيًا منهما.</p><p dir="RTL" style="margin-left:0in; text-align:right; text-indent:0in">يُمكن إعطاء اولترافيست-370 للمرضى الذين لم تعد كليتهم تعمل بشكل صحيح والذين يحتاجون لغسيل الكلى لإجراء فحوصات إشعاعية، حيث يُمكن التخلص من وسائط التباين التي تحتوي على اليود عبر غسيل الكلى. وينبغي إجراء غسيل الكلى مباشرة بعد الفحص الإشعاعي.</p><p dir="RTL" style="margin-left:0in; text-align:right; text-indent:0in">في حالة الفشل الكلوي الحاد، يُمكن لأي اضطراب وظيفي حاد إضافي أن يؤخر بشكل خطير إفراز وسيط التباين من الكبد، الأمر الذي قد يتطلب معه غسيل الكلى.</p><p dir="RTL" style="margin-left:0in; text-align:right; text-indent:0in">&nbsp;</p><p dir="RTL" style="margin-left:0in; text-align:right; text-indent:0in"><em>الداء السكري</em></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">بغرض تجنب زيادة تكوين الأحماض في الدم (الحُماض اللاكتيكي)، ينبغي على مرضى داء السكري الذين يتلقون العلاج بالميتفورمين قياس مستويات الكرياتينين في الدم قبل الحقن داخل الأوعية الدموية لوسط التباين المعالج باليود. (يُرجى الاطلاع على قسم &quot;الأدوية الأخرى واولترافيست-370&quot;).</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">وينبغي النظر في التوقف عن تناول الميتفورمين وفقًا لنتائج اختبارات وظائف الكلى.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">بالنسبة <em><u>لمرضى الطوارئ</u></em> وفي حالة وجود وظيفة كلوية مقيدة أو غير معروفة، يجب على الأطباء تحديد المخاطر بدقة مقابل فوائد الفحص المعزز بالتباين كما يجب عليهم اتخاذ الاحتياطات اللازمة: التوقف عن العلاج بالميتفورمين وترطيب المريض ومراقبة قيم وظائف الكلى والمصل اللاكتات ودرجة الحموضة ومراقبة المريض عن كثب بحثًا عن العلامات السريرية للحُماض اللاكتيكي.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><em>اضطرابات نظام التخثر</em></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">ترتبط فحوصات وسائط التباين للأوعية الدموية باستخدام قسطرة بخطر التسبب في انسداد الأوعية الدموية في هيئة جلطات دموية (انصمام خُثارِي). وبالإضافة إلى وسيط التباين نفسه، قد تساهم العديد من العوامل الأخرى في حدوث انسداد الوريد بسبب الجلطات الدموية (حالات الانصمام الخثاري)؛ متضمنة: مدة إجراء الفحص وعدد الحقن ونوع القسطرة ومواد الحقن والأمراض الكامنة الحالية والأدوية المصاحبة لها. لتقليل المخاطر المرتبطة بالفحص من انسداد الأوردة بسبب الجلطات الدموية (خطر الإصابة بتجلط الدم وانسداد الوعاء الدموي)، فلابد من إجراء تقنيات الفحص بأكبر قدر ممكن من الدقة عند تصوير الأوعية الدموية، ويجب غسل القسطرة بشكل متكرر بمحلول ملحي فسيولوجي (مع إضافة الهيبارين إن أمكن) ، ويجب أن يكون الفحص قصيرًا قدر الإمكان.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><em>اضطرابات الجهاز العصبي المركزي</em></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">يجب توخي الحذر فيما يتعلق بالحقن داخل الأوعية الدموية (في الأوعية الدموية) لدى المرضى الذين يعانون من احتشاء دماغي حاد أو نزيف حاد داخل الجمجمة، ولدى المرضى الذين يعانون من أمراض تسبب تلف الحاجز الدموي الدماغي، وكذلك لدى المرضى الذين يعانون من وذمة دماغية<strong> </strong>أو إزالة الميالين الحادة. وبالنسبة للمرضى الذين يعانون من أورام المخ أو النقائل الدماغية أو الصرع، قد يزداد تواتر النوبات الدماغية بعد تناول وسائط التباين. ويمكن تكثيف الأعراض العصبية الناجمة عن أمراض الأوعية الدموية في الدماغ (أمراض الأوعية الدموية الدماغية) أو أورام المخ أو نقائل الدماغ أو العمليات التنكسية أو الالتهابية بتناول وسائط التباين. وقد يؤدي استخدام وسائط التباين في الشريان إلى حدوث تشنجات في الأوعية الدموية والأعراض المصاحبة لعدم كفاية إمداد الدماغ بالدم. ويُعاني المرضى المصابون بأمراض دماغية وعائية مصحوبة بأعراض أو سكتة دماغية حديثة أو نوبات إقفارية عابرة متكررة من خطر متزايد لحدوث المضاعفات العصبية الناجمة عن وسائط التباين.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><em>عوامل الخطر الأخرى</em></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">قد يتعرض المرضى الذين يعانون من مرض معين في الغدة الكظرية (ورم القواتم) لخطر متزايد يتمثل في نشوء نوبة ضغط الدم (نوبة فرط الضغط) بعد حقن وسيط التباين داخل الأوعية الدموية (الحقن في الأوعية الدموية).</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">بعد حقن وسيط التباين (الحقن في الأوعية الدموية)، قد يزيد اولترافيست-370 من أعراض مرض ضعف العضلات (الوهن العضلي الوبيل).</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><em><u>&nbsp;</u></em></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">الاستخدام في تجاويف الجسم</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">ينبغي أن يخضع المرضى المصابون بالتهاب البنكرياس الحاد (التهاب البنكرياس) والقنوات الصفراوية الملتهبة الحادة (التهاب الأقنية الصفراوية) لتقييم دقيق للمخاطر والفوائد قبل استخدام اولترافيست-370 للفحص بالمنظار للقناة الصفراوية والبنكرياس (تخطيط القنيات البنكرياسية و الصفراوية عبر التنظير الداخلي الراجع &quot;ERCP&quot;). ويجب تأجيل الفحص حتى تهدأ الأعراض الحادة (من 3 إلى 4 أسابيع)، ما لم تكن هناك حاجة لاتخاذ تدابير علاجية فورية مثل إزالة الحجر المعوق (انسداد بسبب حصوات في القناة الصفراوية) أو مجازة التضيق.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:17.85pt; text-align:right"><strong>الأدوية الأخرى واولترافيست-370</strong></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right; text-indent:0in">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right; text-indent:0in">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تستخدم أية أدوية أخرى، أو تناولت أو استخدمت أية أدوية مؤخرًا، أو قد تناولهم أو تستخدمهم فيما بعد. ويشمل هذا أيضًا الأدوية التي لا تتناولها بانتظام، ولكن ربما تكون قد استخدمتها خلال الأيام التي تسبق الفحص الإشعاعي.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right; text-indent:0in">من المهم بصفة خاصة إبلاغ الطبيب إذا كنت تتناول أيًّ من الأدوية التالية:</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>بيغوانيد</strong> (ميتفورمين, دواء يستخدم لعلاج داء السكري): إذا كنت تعاني من الفشل الكلوي الحاد أو مرض الكلى المزمن، فقد يكون هناك تأخير في التخلص من مركبات البيغوانيد، والتي تتراكم بعد ذلك في الدم وقد تؤدي إلى الحُماض اللاكتيكي (الكثير من الأحماض في الدم).</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right; text-indent:0in">نظرًا لأن استخدام اولترافيست-370 قد يسبب مشاكل في الكلى أو يزيد من سوء مشاكل الكلى الحالية، فقد يزداد خطر إصابتك بالحُماض اللاكتيكي.</p><p dir="RTL" style="margin-left:0in; margin-right:17.85pt; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right; text-indent:0in">وينطبق ذلك بصفة خاصة إذا كنت تعاني بالفعل من قصور في وظائف الكلى (يُرجى الاطلاع على القسم الفرعي &quot;الاستخدامات داخل الأوعية&quot;؛ &quot;اضطرابات وظائف الكلى&quot;). وينبغي النظر بعناية في مدى استصواب التوقف عن العلاج بالميتفورمين وفقًا لنتائج اختبارات وظائف الكلى.</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>إنترلوكين-2:</strong> لقد ارتبط العلاج السابق (حتى عدة أسابيع) بدواء إنترلوكين 2 (عقار للسرطان) بزيادة خطر تأخر ظهور تفاعلات الوسائط التباين مع استخدام اولترافيست-370.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right; text-indent:0in">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>النظائر المشعة: </strong>بعد الحقن داخل الأوعية الدموية (الاستخدام في الأوعية الدموية)، يُمكن لوسائط التباين التي تحتوي على اليود أن تقلل من قدرة أنسجة الغدة الدرقية على امتصاص النظائر. ونتيجة لذلك، قد يتعطل تشخيص وعلاج وظيفة الغدة الدرقية المضطربة بالنظائر المشعة الدرقية لعدة أسابيع بعد استخدام اولترافيست-370، وحتى لفترة أطول في الحالات المنفردة.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>الحمل والرضاعة</strong></p><p dir="RTL" style="text-align:right">يُرجى استشارة طبيبك قبل استخدام هذا الدواء في حالة الحمل أو الرضاعة الطبيعية، أو إذا كنتِ تعتقدين بأنكِ حامل أو تخططين لذلك.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><u>الحمل</u></p><p dir="RTL" style="text-align:right">لم تجر دراسات جيدة المراقبة والتحكم على النساء الحوامل. لذلك، لم تُثبت سلامة استخدام اولترافيست-370 أثناء الحمل البشري بشكل كافٍ. ولم تظهر الدراسات التي أجريت على الحيوانات باستخدام أيوبرومايد أي دليل على وجود تأثير ضار أثناء الحمل فيما يتعلق بنمو النطفة/ الجنين أو الولادة أو نمو الأطفال حديثي الولادة بعد استخدام أيوبرومايد لأغراض التشخيص لدى البشر.</p><p dir="RTL" style="text-align:right">يعرض فحص الأشعة السينية كل من الأم والجنين الذي لم يولد بعد للإشعاع. ونظرًا لضرورة تجنب التعرض للإشعاع بشكل عام أثناء الحمل قدر الإمكان، فيحتاج طبيبك إلى تقييم المخاطر المحتملة المرتبطة بالفحوصات الإشعاعية بعناية، سواء باستخدام وسيط التباين أو بدونه. وبالإضافة إلى ضرورة حماية الجنين من الإشعاع، فيتعين أيضًا مراعاة حساسية الغدة الدرقية للجنين تجاه اليود عند استخدام وسائط التباين التي تحتوي على اليود.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><u>الرضاعة الطبيعية</u></p><p dir="RTL" style="text-align:right">لم تُدرس سلامة عقار اولترافيست-370 لدى الرضع الذين يرضعون رضاعة طبيعية. ولا يُتوقع أن تؤدي الكميات الصغيرة من المكون الفعال في اولترافيست-370 إلى إلحاق الضرر بالرضيع الذي يرضع رضاعة طبيعية، نظرًا لأن كميات صغيرة فقط من المكون الفعال في اولترافيست-370 تنتقل إلى حليب الثدي (يُرجى الاطلاع أيضًا على قسمي &quot;الاحتياطات والتحذيرات&quot;؛ &quot;اضطرابات وظائف الغدة الدرقية&quot;. ولتجنب الإفراط المحتمل لتعرض الرضيع الذي يرضع طبيعيًا لليوديد (خطر منع تخليق هرمون الغدة الدرقية) ولأسباب تتعلق بالسلامة، يُوصى بتعليق الرضاعة الطبيعية لمدة يومين للأطفال الذين تقل أعمارهم عن 4 أشهر والتخلص من أي لبن مشروب.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL" style="text-align:right">لم تُجرّ دراسات حول التأثيرات على القدرة على القيادة واستخدام الآلات بعد استخدام اولترافيست.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>يحتوي اولترافيست-370 على الصوديوم</strong></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">يحتوي هذا الدواء على أقل من 1 ميليمول من الصوديوم (23 مجم) لكل جرعة (بناءً على متوسط الكمية للشخص الذي يزن 70 كجم)، أي &quot;خالٍ من الصوديوم&quot; في الأساس.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right; text-indent:0in">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:0in; text-align:right">يُحقن اولترافيست-370 أو يُسرّب في وعاء دموي (الحقن داخل الأوعية الدموية أو التسريب الوريدي) أو إدخاله في تجاويف الجسم (الاستخدام داخل التجويف).</p><p dir="RTL" style="margin-left:0in; text-align:right">سيحقنك الطبيب أو أخصائي الرعاية الصحية المدرب بعقار اولترافيست-370.</p><p dir="RTL" style="margin-left:0in; text-align:right">في حالة حقن اولترافيست-370 داخل الأوعية الدموية (الحقن داخل الأوعية الدموية)، سيفحصك طبيبك بحثًا عن أي أمراض كامنة وسيسألك عن أي أدوية تتناولها/تستخدمها، حيث قد تتسبب في حدوث الانصمام الخثاري (انسداد الأوعية الدموية بسبب جلطة دموية).</p><p dir="RTL" style="margin-left:0in; text-align:right">يجب التأكد من تناول كمية كافية من السوائل قبل استخدام اولترافيست-370 وبعده.</p><p dir="RTL" style="margin-left:0in; text-align:right">سيتصرف طبيبك على النحو التالي</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->سيكون حريصًا بشكل خاص على إجراء عملية فحص الأوعية الدموية (تصوير الأوعية الدموية)،</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->سيشطف بشكل متكرر القسطرة بمحلول ملحي (ويستخدم الهيبارين إن أمكن - دواء لتخثر الدم)،</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->سيبقي الفحص قصيرًا قدر الإمكان لتقليل مخاطر الإصابة بجلطة دموية مرتبطة بالفحص في الأوعية الدموية (تجلط الدم) أو احتقان (تضيق أو انسداد) تجويف الأوعية الدموية بسبب صمة، مثل جلطة دموية (انسداد الوعاء الدموي).</p><p dir="RTL" style="margin-left:0in; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0in; text-align:right">سيُحدد طبيبك الجرعة الصحيحة من وسيط التباين للفحص الإشعاعي. وإذا كنت مهتمًا، فاطلب من الطبيب شرح الفحص لك.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>كيفية تحديد جرعة دواء اولترافيست-370</strong></p><p dir="RTL" style="margin-left:0in; text-align:right"><strong>معلومات عامة</strong></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">تُحدد الجرعة على أساس العمر والوزن ووظائف القلب والكلى والحالة الصحية العامة والسؤال السريري المحدد وطريقة الفحص ومنطقة الجسم التي جرى فحصها.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">سيحدد الطبيب المعالج تركيز اليود المناسب والجرعة اللازمة لكل مريض على حدة. وتتوفر نظرة عامة على الجرعات الموصي بها للتركيزات المختلفة لمحاليل أيوبرومايد لكل منطقة من الجسم المراد تصويرها في شكل جدول في نهاية هذه النشرة.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">ينبغي عدم تجاوز الجرعة الإجمالية البالغة 1.5 جم من اليود لكل كجم من وزن الجسم (ما يعادل حوالي 4 مل من اولترافيست-370 لكل كجم من وزن الجسم) في أي يوم من أيام الفحص.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">يجب تدفئة اولترافيست-370 لدرجة حرارة الجسم قبل استخدامه، مما يُحسن القدرة على التحمل ويُسهل الحقن بسبب انخفاض اللزوجة.</p><p dir="RTL" style="margin-left:0in; text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="margin-left:0in; text-align:right"><strong>الإرشادات التالية تتعلق بأنواع الاستخدام المختلفة</strong></p><p dir="RTL" style="margin-left:0in; text-align:right">ما لم يُنص على خلاف ذلك، تنطبق توجيهات الجرعات التالية على مجالات الاستخدام المحددة:</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><em>تصوير الكلى والمسالك البولية (التصوير الوريدي للجهاز البولي)</em></p><p dir="RTL" style="margin-left:0in; text-align:right">من المهم ملاحظة أنه عند إجراء التصوير الوريدي للجهاز البولي، يلزم إعطاء جرعات عالية نسبيًا من وسيط التباين للرضع، بسبب ضعف قدرة التركيز الفسيولوجية للوحدة الكلوية غير الناضجة في الكلية الطفولية.</p><p dir="RTL" style="margin-left:0in; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0in; text-align:right"><em>التصوير المقطعي المحوسب (</em><em>CT</em><em>)</em></p><p dir="RTL" style="margin-left:0in; text-align:right">يجب إعطاء اولترافيست-370 كحقنة وريدية سريعة، وإذا أمكن، بمساعدة حاقن عالي الضغط. وعند استخدام الماسحات الضوئية البطيئة، من أجل تحقيق مستويات دم ثابتة نسبيًا، نوصي بحقن نصف الجرعة على شكل بُلَعة والباقي خلال 2-6 دقائق، حتى إذا تعذر الحفاظ على ذروة ثابتة. وتبدأ عملية المسح عند الانتهاء من مرحلة الحقن الأولية.</p><p dir="RTL" style="margin-left:0in; text-align:right">عند إجراء التصوير المقطعي الحلزوني، وخاصة تقنيات الشرائح المتعددة، تُجمع مجموعة متنوعة من البيانات بينما يحبس المريض أنفاسه. ومن أجل تحسين تأثير الحقن الوريدي على شكل بُلَعة في المنطقة المعنية (يتحقق التعزيز الأمثل في أوقات مختلفة في الأنسجة المتغيرة مرضيًا)، يوصى باستخدام حاقن أوتوماتيكي عالي الضغط وحقنة على شكل بُلَعة.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">عند إجراء التصوير المقطعي المحوسب، تُحدّد الكمية المطلوبة من وسائط التباين ومعدل الإعطاء بالنسبة للأعضاء التي سيتعين فحصها والسؤال التشخيصي المطروح، ولكن أيضًا مع مراعاة الجهاز المتاح بالفعل للفحص المحدد (مثل أوقات المسح الضوئي وتشكيل الصورة). ويُوصى بالتسريب عند استخدام أجهزة بطيئة العمل، وحقن البُلَعة للماسحات الضوئية السريعة.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><em>تصوير الأوعية بالطرح الرقمي (</em><em>DSA</em><em>)</em></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">في كثير من الحالات، قد يُنتج تصوير الأوعية بالطرح الرقمي داخل الشرايين صورًا مُحسَّنة بقوة للأوعية الكبيرة وشرايين العنق والكلى والأطراف، حتى في الحالات التي يكون فيها التركيز المستخدم لمحلول اولترافيست-370 غير كافٍ لتصوير الأوعية المعتاد. ولذلك يوصى بهذه الطريقة للمرضى الذين يعانون من اختلال وظائف الكلى.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><em>تصوير تجاويف الجسم</em></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">عند إجراء تصوير المفاصل وتصوير الرحم والبوق وتخطيط القنيات البنكرياسية و الصفراوية عبر التنظير الداخلي الراجع، يجب حقن وسيط التباين تحت المراقبة الفلورية.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>معلومات إضافية لفئات معينة من المرضى</strong></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><em>حديثي الولادة والرضع</em></p><p dir="RTL" style="margin-left:0in; text-align:right">الرضع الذين تقل أعمارهم عن سنة واحدة، وخاصة الأطفال حديثي الولادة، معرضون لاضطرابات توازن الكهارل والتغيرات في الدورة الدموية (التغيرات الديناميكية الدموية). وسيختار الطبيب جرعة وسيط التباين بعناية وإجراء الفحص الإشعاعي بطريقة تراعي حالة المريض الفعلية.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><em>المرضى الذين يعانون قصورًا في وظائف الكلى</em></p><p dir="RTL" style="margin-left:0in; text-align:right">نظرًا لأن أيوبرومايد، المكون الفعال في اولترافيست-370، يُفرز بشكل شبه دائم عن طريق الكلى في شكل غير متغير، فإن الوقت اللازم للتخلص من أيوبرومايد يكون أطول لدى مرضى الفشل الكلوي. ويجب أن تبقى جرعة وسيط التباين للمرضى الذين يعانون قصورًا في وظائف الكلى منخفضة قدر الإمكان من أجل تقليل مخاطر أي إصابة في الكلى ناتجة عن وسيط التباين (يُرجى الاطلاع أيضًا على قسم &quot;الاحتياطات والتحذيرات&quot;).</p><p dir="RTL" style="margin-left:0in; text-align:right">لمزيد من المعلومات حول استخدام اولترافيست-370 والتعامل معه، يُرجى الاطلاع على الإرشادات الواردة في نهاية هذه النشرة (يُرجى الاطلاع على قسم &quot;المعلومات التالية مخصصة للأطباء والطاقم الطبي المؤهل فقط&quot;).</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>ملاحظات حول الاستخدام العملي</strong></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">يتوفر عقار اولترافيست-370 كمحلول جاهز للاستخدام شفاف عديم اللون مائل إلى لون الأصفر الباهت. ويجب فحص وسيط التباين بصريًا قبل استخدامه. ونظرًا لأن اولترافيست-370 عبارة عن محلول عالي التركيز، فقد يحدث التبلور في حالات نادرة (شكل حليبي عكر ورواسب سفلية أو بلورات عائمة أو أيًا منهم). ويحظر استخدام وسيط تباين إذا تغير لونه بشدة أو إذا كانت الجزيئات (متضمنة البلورات) مرئية أو في حالة تلف الحاوية.</p><p dir="RTL" style="margin-left:0in; text-align:right">يجب سحب محلول وسيط التباين في المحقنة أو الحاوية المرفقة بجهاز التسريب قبل إجراء الفحص مباشرة.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">ويُمكن ثقب السدادة المطاطية مرة واحدة فقط لمنع دخول كميات كبيرة من الجسيمات الدقيقة إلى المحلول عبر السدادة. ويوصى باستخدام قنية طويلة الطرف بقطر يبلغ 18 جم بحد أقصى لثقب السدادة ولرسم وسيط التباين (قنيات السحب الخاصة ذات الفتحة الجانبية مناسبة بوجه خاص).</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">تُعبأ محاليل وسائط التباين كمحاليل للحقن للاستخدام مرة واحدة فقط؛ ويجب التخلص من أي وسائط تباين متبقية بعد إجراء الفحص والتخلص منها بشكل مناسب.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">عند استخدام النظام الآلي لإعطاء منتج طبي، يجب على الشركة المصنعة للمنتج الطبي تقديم دليل على ملاءمة أي استخدام من هذا القبيل، فضلًا عن عقم وسيط التباين. ويجب اتباع تعليمات استخدام المنتج الطبي المعني بدقة. كما يحظر الاستعانة بأنظمة الاستخدام الآلي لدى الرضع والأطفال الصغار.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">تنطبق القواعد التكميلية التالية عند استخدام خراطيش بلاستيكية معبأة مسبقًا: لا يُسمح إلا للطاقم الطبي المؤهل فحسب بإعطاء وسائط التباين ويجب دائمًا تنفيذ الإجراء باستخدام الطرق والأجهزة المناسبة. ويجب اتباع تقنيات المعالجة المعقمة بصرامة لجميع الحقن التي تحتوي على وسائط التباين. كما يجب إعطاء وسائط التباين بحقنة مناسبة؛ ويُرد نوع الحاقن المطلوب بوضوح على الحاوية نفسها. ويجب التقيد بأي تعليمات واردة من الشركة المصنعة بدقة.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>إذا تلقيت كمية من اولترافيست-370 أكثر من الموصوف لك</strong></p><p dir="RTL" style="text-align:right">أبلّغ طبيبك على فورًا إذا تلقيت كمية من اولترافيست-370 أكثر من الموصوف لك ولم تشعر بصحة جيدة.</p><p dir="RTL" style="margin-left:0in; text-align:right">قد يؤثر تناول جرعة زائدة على الجهاز الرئوي والقلب والأوعية الدموية، مما قد يسبب آثارًا غير مرغوب فيها وحتى ردود فعل تهدد الحياة. وتشمل أعراض الجرعة الزائدة عدم توازن سوائل الجسم والكهارل والفشل الكلوي ومضاعفات في القلب والأوعية الدموية والجهاز التنفسي (المتعلقة بوظائف التنفس).</p><p dir="RTL" style="margin-left:0in; text-align:right">لهذا السبب، يتضمن علاج تناول الجرعة الزائدة الإبقاء على جميع وظائف الحفاظ على الحياة والشروع في علاج الأعراض المحددة بعناية. وفي حالة تناول جرعة زائدة عرضية، يجب مراقبة اختلال توازن الماء/الكهارل ووظائف الكلى. وقد يقرر طبيبك إجراء غسيل الكلى لإزالة اولترافيست-370 من جسمك.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">إذا كان لديك أية أسئلة إضافية حول هذا الدواء، يُرجى استشارة الطبيب.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">كما هو الحال في جميع الأدوية، قد يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL" style="text-align:right">يُرجى إخبار طبيبك أو الصيدلي إذا لاحظت أي آثار جانبية أو تظن أنك تُعاني من مشاكل مرتبطة بتلقي وسيط تباين الأشعة السينية. وينطبق هذا أيضًا إذا لم ترد المشاكل ضمن الآثار الجانبية الواردة في هذه النشرة. يُرجى ملاحظة أن الآثار الجانبية قد تحدث أيضًا بعد فترة من الوقت &ndash; ربما بعد فحص الأشعة السينية بفترة كبيرة.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">وتُعد الآثار الجانبية الأكثر شيوعًا التي لوحظت في المرضى بعد استخدام اولترافيست-370 (&ge;4%) الصداع والغثيان وتوسع الأوعية الدموية (تمدد الأوعية الدموية).</p><p dir="RTL" style="margin-left:0in; text-align:right">وتُعد أخطر الآثار الجانبية التي لوحظت في المرضى بعد استخدام اولترافيست-370 الصدمة والصدمة شبه تأقية وتوقف التنفس وصعوبة في التنفس (التشنج القصبي) وتورم في الحنجرة (وذمة الحنجرة) وتورم في البلعوم (وذمة البلعوم) والربو والغيبوبة وانخفاض تدفق الدم إلى الدماغ (نقص تروية الدماغ/ الاحتشاء الدماغي الحاد) والسكتة الدماغية وتورم الدماغ (الوذمة الدماغية) والنوبات/التشنج الدماغي وعدم انتظام ضربات القلب (اضطراب نبضات القلب) والسكتة القلبية وألم في الصدر ناتج عن نقص إمداد القلب بالأكسجين (نقص تروية عضلة القلب) والنوبة القلبية (احتشاء عضلة القلب) وقصور القلب وتباطؤ معدل ضربات القلب (بطء القلب) وزرقة لون الجلد والأغشية المخاطية بسبب نقص الأكسجين (الزُرقة) وانخفاض ضغط الدم وضيق التنفس (الزلة التنفسية) وتراكم السوائل في الرئتين (الوذمة الرئوية) وضيق في التنفس (قصور في الجهاز التنفسي).</p><p dir="RTL" style="text-align:right">قد تحدث أنواع مختلفة من الآثار الجانبية بالاقتران مع استخدام وسائط التباين التي تحتوي على اليود. ونحن نفرق بين تفاعلات الحساسية الزائفة التي لا يمكن التنبؤ بها (يُرجى الاطلاع أيضًا على قسم &quot;الاحتياطات والتحذيرات&quot; وتفاعلات فرط الحساسية في شكل تفاعلات الحساسية والتأق أو الحساسية الزائفة، فضلًا عن التفاعلات السمية العضوية التي يمكن تفسيرها دوائياً والتي يمكن التنبؤ بها. وقد تحدث أيضًا تفاعلات الحساسية الزائفة والتفاعلات السمية العضوية في وقت واحد، ولا يُمكن دائمًا تصنيف الحالة المحددة بشكل نهائي.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>الأعراض الشائعة:</strong> يُعاني منها ما يصل إلى مريض واحد تلقي العلاج من أصل 10</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات التذوق (خلل التذوق)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية/ضعف البصر</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر/الشعور بضيق في الصدر</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم (ارتفاع التوتر الشرياني)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توسع الأوعية الدموية (تمدد الأوعية الدموية)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الآلام</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل في موقع الحقن بأنواع مختلفة: مثل الألم والإحساس بالحرارة<sup>&sect;)</sup>, والتورم<sup>&sect;)</sup> (الوذمة), والتهاب<sup>&sect;)</sup> الأنسجة الرخوة المحيطة وإصابتها<sup>&sect;) </sup>إذا خرج اولترافيست-370 من موقع الحقن)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الوجه</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>الأعراض غير الشائعة:</strong> يُعاني منها ما يصل إلى مريض واحد تلقي العلاج من أصل 100</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات فرط الحساسية/شبيهة بالحساسية (تفاعلات تأقاية):</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right">صدمة شبه تأقية<sup>&sect;)*)</sup>, وتوقف التنفس<sup>&sect;)*)</sup>, وتقلصات في عضلات الشعب الهوائية<sup>*)</sup> (التشنج القصبي), وتورم في منطقة الحنجرة<sup>*) </sup>(وذمة الحنجرة)/تورم في البلعوم<sup>*) </sup>(وذمة البلعوم)/تورم في الوجه (وذمة الوجه), (تورم اللسان<sup>&sect;)</sup> (وذمة اللسان) وتشنج الحنجرة (تشنج في منطقة الحنجرة/تشنج في منطقة البلعوم<sup>&sect;)</sup> (تشنج الحنجرة/تشنج البلعوم), والربو<sup>&sect;)*)</sup>, التهاب الملتحمة<sup>&sect;)</sup> (الرمد) والتدمع<sup>&sect;)</sup>والعطس والسعال وتورم الغشاء المخاطي (الوذمة المخاطية) والتهاب الغشاء المخاطي<sup>&sect;)</sup> (التهاب مخاطية الأنف), خشونة الصوت<sup>&sect;)</sup>, تهيج الحلق<sup>&sect;)</sup>, الجدري الكاذب(الشَرَى) والحكة (الحكة الجلدية) وتورم في الجلد والأغشية المخاطية (الوذمة الوعائية)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوعي/الإغماء وانخفاض ضغط الدم مع انخفاض معدل ضربات القلب (تفاعلات وعائية مبهمة)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التوهان</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الضجر</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حساسية غير اعتيادية للجلد مثل الحرق أو الوخز أو الحكة أو الخدر (التنمل)/إحساس محدود باللمس أو إحساس بالجلد (اختلال الإحساس)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة الانتباه/ النعاس (الاستلقاء)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب<sup>*)</sup> (اضطراب نبضات القلب)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم<sup>*)</sup> (هبوط ضغط الدم)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق النفس<sup>*)</sup> (الزلة التنفسية)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمعدة (ألم في البطن)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الأنسجة (الوذمة)</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>الأعراض النادرة: </strong>يُعاني منها ما يصل إلى مريض واحد تلقي العلاج من أصل 1,000</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات القلق</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توقف القلب<sup>*)</sup></p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر بسبب نقص إمداد القلب بالأكسجين<sup>*)</sup> (نقص تروية عضلة القلب)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخفقان السريع</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt"><strong>آثار جانبية غير معروفة: لا يمكن توقعها من خلال البيانات المتاحة</strong></p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات فرط نشاط الغدة الدرقية المهددة للحياة (نوبة التسمم الدرقية)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات وظائف الغدة الدرقية</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غيبوبة<sup>*)</sup></p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص إمداد الدم للدماغ<sup>*) </sup>(اقفار الدماغ /الاحتشاء الدماغي)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكتة الدماغية<sup>*)</sup></p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الدماغ<sup>a</sup><sup>)*) </sup>(وذمة دماغية)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات دماغية/تشنجات<sup>a</sup><sup>)*)</sup></p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف البصر المؤقت<sup>a</sup><sup>)</sup> (العمى القشري)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوعي</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاستثارة والأرق (التهيج)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الذاكرة</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتعاش (الرجفة)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الكلام</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشلل الجزئي/الكامل (الشلل الجزئي/العجز)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات السمع</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزمة قلبية<sup>*)</sup> (انسداد عضلة القلب)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سكتة قلبية<sup>*)</sup></p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء ضربات القلب<sup>*) </sup>(بطء نبضات القلب)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع ضربات القلب (عدم انتظام ضربات القلب)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لون مزرق على الجلد والغشاء المخاطي بسبب نقص الأكسجين<sup>*) </sup>(الازرقاق)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صدمة<sup>*)</sup></p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد الأوعية الدموية عن طريق جلطات الدم<sup>a</sup><sup>)</sup> (حالات تجلط الدم)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انقباض مفاجئ يشبه التشنج في أوعية نقل الدم<sup>a</sup><sup>)</sup> (التشنج الوعائي)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تراكم السوائل في الرئتين<sup>*) </sup>(وذمة رئوية)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس<sup>*) </sup>(قصور الجهاز التنفسي)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات البلع (صعوبة البلع)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الغدة اللعابية</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض الجلد مع تشكل بثور (مثل متلازمة ستيفنز جونسون أو لايل)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي (الطفحية)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد (التهاب جلدي)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرق المفرط (فرط التعرق)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط في الأنسجة العضلية مما يؤدي إلى تلف العضلات والأنسجة العصبية، بالإضافة إلى اضطرابات تدفق الدم<sup>a</sup><sup>)</sup> (متلازمة الحيز بعد التسرب)</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات وظائف الكلى<sup>a</sup><sup>)</sup></p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكلوي الحاد<sup>a</sup><sup>)</sup></p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضيق</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القشعريرة</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشحوب</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغييرات في درجة حرارة الجسم</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><sup>&nbsp;</sup></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><em><sup>*)</sup></em><em> تم الإبلاغ عن حالات تهديد للحياة و/أو حالات وفاة</em></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><em><sup>a</sup></em><em><sup>)</sup></em><em> ينطبق فقط على الاستعمال داخل الأوعية الدموية</em></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><em><sup>&sect;)</sup></em><em> لوحظ فقط بعد الإطلاق في الأسواق (معدل تكرار حدوثها غير معروف)</em></p><p dir="RTL" style="text-align:right"><strong><em>&nbsp;</em></strong></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">اطلب الرعاية الطبية فورًا إذا لاحظت أي من العلامات والأعراض التالية (التي لا يُعرف معدل تكرارها):</p><p dir="RTL" style="margin-left:0in; margin-right:.25in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->بقع حمراء على الجسم، تشبه التلطيخات أو الدوائر، وغالبًا ما تحتوي على بثور في وسطها، تقشير الجلد، قرح الفم والحلق والأنف والأعضاء التناسلية والعيون. يمكن أن تسبق هذا الطفح الجلدي الخطير حمى وأعراض تشبه أعراض الإنفلونزا (متلازمة ستيفنز جونسون، تقشر الانسجة المتموتة البشروية التسممي).</p><p dir="RTL" style="margin-left:0in; margin-right:.25in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->طفح جلدي واسع الانتشار، وارتفاع درجة حرارة الجسم وتضخم الغدد الليمفاوية (متلازمة الطفح الدوائي وأعراض كثرة الخلايا اليوزينيّة في الدم أو متلازمة فرط الحساسية ضد الأدوية).</p><p dir="RTL" style="margin-left:0in; margin-right:.25in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->طفح جلدي أحمر قشري واسع الانتشار مع نتوءات تحت الجلد وبثور مصحوبة بالحمى بعد إجراء التصوير (بثور طفح جلدي معممة حادة).</p><p dir="RTL" style="margin-left:0in; margin-right:.25in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->اضطراب دماغي قصير المدى (اعتلال الدماغ) الذي يمكن أن يؤدي إلى فقدان الذاكرة، والارتباك، والهلوسة، وصعوبات في الرؤية، وفقدان البصر، والنوبات، وفقدان التوازن، وفقدان الحركة في أحد جانبي الجسم، ومشاكل في الكلام، وفقدان الوعي.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>الاستخدام داخل الأوعية الدموية (الحقن في الأوعية الدموية)</strong></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">عادة ما تكون الآثار الجانبية المرتبطة بالحقن داخل الأوعية الدموية لوسط التباين المعالج باليود خفيفة إلى معتدلة ومؤقتة في طبيعتها. ومع ذلك، يمكن أن تحدث ردود فعل خطيرة ونادرة مهددة للحياة والتي تتطلب علاجا طارئًا سريعًا وفعالًا.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">تحدث ردود الفعل تجاه الوسط التبايني بشكل أكثر تكرارًا وتشتد حدتها بعد الحقن داخل الأوعية الدموية، مما هو الحال عندما يتم إدخالها في تجاويف الجسم (الحقن داخل القناة وداخل التجويف).</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong><em>&nbsp;</em></strong></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>الاستخدام في تجاويف الجسم</strong></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">نظرًا لأن هناك كميات صغيرة من وسائط التباين يمكن أن تمر كذلك في الأوعية الدموية بعد إدخال وسائط التباين في تجاويف الجسم (داخل القناة، الحقن داخل التجويف)، عند استخدام طريقة الحقن هذه، يمكن أن تحدث ردود فعل مشابهة للحساسية مثل تلك التي وصفت أيضًا بالنسبة لحقن وسائط التباين في الأوعية الدموية.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">عند تصوير تجاويف الجسم، تميل الأعراض إلى الحدوث كدالة للمنطقة التي تخضع للفحص، وفي معظم الحالات، تحدث بسبب تقنيات الفحص المختارة. تحدث معظم الآثار السلبية التي تحدث بعد الإدخال في تجاويف الجسم في غضون ساعة واحدة بعد الفحص.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">قد يحدث ألم بسبب التمدد عند ملء تجاويف الجسم بوسائط التباين.</p><p dir="RTL" style="margin-left:0in; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0in; text-align:right">بالإضافة إلى الآثار الجانبية المذكورة أعلاه، بعد<strong> فحوصات تصوير البنكرياس والأقنية الصفراوية بالتنظير الباطني بالطريق الراجع،</strong> تم الإبلاغ أيضًا عن زيادة مؤقتة (قابلة للعلاج) في إنزيمات البنكرياس (الأميلاز والليباز) وبداية التهاب البنكرياس (التهاب البنكرياس)، بما في ذلك التهاب البنكرياس النخري (الأنسجة الميتة). غير معروف معدل تكرار حدوث هذه الآثار الجانبية. والسبب في ذلك قد يكون زيادة الضغط في قنوات البنكرياس الصغيرة، بسبب وجود كمية زائدة من وسائط التباين يتم حقنها.</p><p dir="RTL" style="margin-left:0in; text-align:right">تم الإبلاغ عن حالات غير شائعة من مشاكل الجهاز الهضمي بعد ابتلاع وسائط التباين.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>الإبلاغ عن حدوث آثار الجانبية</strong></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">يُرجى التحدث مع طبيبك أو الصيدلي في حال تعرضك لأية آثار جانبية. وتتضمن هذه الآثار الجانبية تلك التي لم يرد ذكرها في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:justify"><strong>وسائل الإبلاغ عن أي أثر (آثار) جانبية:</strong></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:justify">المركز الوطني لسلامة الدواء (NPC).</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:justify">فاكس: 7662 - 205 - 11 - 966 +</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:justify">مركز الاتصال للهيئة العامة للغذاء والدواء: 19999.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:justify">البريد الإلكتروني: npc.drug@sfda.gov.sa.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:0in; text-align:right">ُحفظ هذا الدواء بعيدًا عن متناول الأطفال.</p><p dir="RTL" style="margin-left:0in; text-align:right">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الموضح على العبوة أو العلبة الكرتون بجوار &quot;تاريخ انتهاء الصلاحية&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر المذكور.</p><p dir="RTL" style="margin-left:0in; text-align:right">&nbsp;</p><p dir="RTL" style="margin-left:0in; text-align:right"><strong>ظروف التخزين</strong></p><p dir="RTL" style="margin-left:0in; text-align:right">يُحفظ بعيدًا عن الضوء والأشعة السينية.</p><p dir="RTL" style="margin-left:0in; text-align:right">عدم الحفظ في دجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL" style="text-align:right">يُحظر استخدام وسائط التباين التي يحدث لها تغير شديد في اللون، أو التي تحتوي على جسيمات، أو إذا كانت الحاوية تالفة.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">هذا المنتج الطبي مخصص للاستخدام لمرة واحدة فقط.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>ملاحظة حول العمر الافتراضي بعد فتح العبوة</strong></p><p dir="RTL" style="margin-left:0in; text-align:right">لقد اتضح الاستقرار الكيميائي والمادي للإعداد الجاهز للاستخدام (محلول للحقن أو التسريب) عند درجة 36-38 درجة مئوية لمدة 10 ساعات. ومن وجهة النظر المكروبيولوجية، ينبغي استخدام الجرعة المُعدة الجاهزة للاستخدام على الفور، ما لم تضمن الطريقة المستخدمة لفتح العبوة عدم وجود خطر التلوث.</p><p dir="RTL" style="margin-left:0in; text-align:right">إذا لم يتم إعطاء الجرعة المُعدة الجاهزة للاستخدام على الفور، يجب على الجراح التأكد من استخدام المحلول المتبقي خلال الفترة الزمنية المحددة وفي ظل الظروف المناسبة.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">لا تتخلص أبدًا من أي أدوية عن طريق مياه الصرف الصحي (مثل التخلص منها في المرحاض أو الحوض). اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>محتويات اولترافيست-370</strong></p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->المادة الفعالة هي أيوبرومايد. يحتوي كل 1 مل من محلول الحقن أو التسريب على 769 ملج من مادة أيوبرومايد (ما يعادل 370 ملجم من اليود المرتبط بالبروتين لكل مل).</p><table dir="rtl" cellspacing="0" cellpadding="0" border="1" style="width:558px"><tbody><tr><td colspan="2" style="vertical-align:top; width:418.15pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify"><strong>محتوى وتركيز المادة الفعالة في اولترافيست-370 وما ينتج عنها من قيم محتوى وتركيز اليود المرتبط بالبروتين</strong></p></td></tr><tr><td style="vertical-align:top; width:283.5pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">تركيز <strong>الأيوبرومايد</strong> (ملجم/مل)</p></td><td style="vertical-align:top; width:134.65pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">769</p></td></tr><tr><td style="vertical-align:top; width:283.5pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">محتوى الأيوبرومايد (جرام) في</p><p dir="RTL" style="margin-left:10.65pt; margin-right:.05in; text-align:justify">زجاجة تحتوي على&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50&nbsp;مل</p><p dir="RTL" style="margin-left:10.65pt; margin-right:.05in; text-align:justify">زجاجة تحتوي على &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 100&nbsp;مل</p></td><td style="vertical-align:top; width:134.65pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">&nbsp;</p><p dir="RTL" style="margin-left:82.25pt; margin-right:.05in; text-align:justify">38.4</p><p dir="RTL" style="margin-left:82.25pt; margin-right:.05in; text-align:justify">76.9</p></td></tr><tr><td style="height:4.1pt; vertical-align:top; width:283.5pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">تركيز <strong>اليود</strong> (ملجم/مل)</p></td><td style="height:4.1pt; vertical-align:top; width:134.65pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">370</p></td></tr><tr><td style="height:3.0pt; vertical-align:top; width:283.5pt"><p dir="RTL" style="margin-left:10.75pt; margin-right:.05in; text-align:justify">محتوى <strong>اليود</strong> للعبوة (جرام) لكل</p><p dir="RTL" style="margin-left:.05in; margin-right:.05in; text-align:justify">زجاجة تحتوي على&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50&nbsp;مل</p><p dir="RTL" style="margin-left:.05in; margin-right:.05in; text-align:justify">زجاجة تحتوي على&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 100&nbsp;مل</p></td><td style="height:3.0pt; vertical-align:top; width:134.65pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">&nbsp;</p><p dir="RTL" style="margin-left:82.25pt; margin-right:.05in; text-align:justify">18.5</p><p dir="RTL" style="margin-left:82.25pt; margin-right:.05in; text-align:justify">37.0</p></td></tr></tbody></table><p dir="RTL" style="margin-left:0in; margin-right:35.45pt; text-align:justify">&nbsp;</p><p dir="RTL" style="margin-left:0in; margin-right:28.35pt; text-align:right; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تشمل المكونات الأخرى: إديتات كالسيوم ثنائي الصوديوم، حمض الهيدروكلوريك (لضبط درجة الحموضة)، التروميتامول والماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right"><strong>مظهر اولترافيست-370 ومحتويات العبوة</strong></p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">يأتي اولترافيست-370 في شكل محلول نقي عديم اللون إلى مصفر شاحب وخالي من الجسيمات للحقن أو التسريب.</p><p>الخصائص الفيزيائية والكيميائية والمادية لاولترافيست-370:</p><table dir="rtl" cellspacing="0" cellpadding="0" border="1"><tbody><tr><td colspan="2" style="height:14.2pt; vertical-align:top; width:269.35pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">الخاصية (وحدة القياس)</p></td><td style="height:14.2pt; vertical-align:top; width:120.5pt"><p dir="RTL" style="margin-left:39.05pt; margin-right:31.95pt; text-align:center">القيمة</p></td></tr><tr><td colspan="2" style="height:14.2pt; vertical-align:top; width:269.35pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">درجة الحموضة</p></td><td style="height:14.2pt; vertical-align:top; width:120.5pt"><p dir="RTL" style="margin-left:67.4pt; margin-right:.05in; text-align:center">6.5 &ndash; 8.0</p></td></tr><tr><td colspan="2" style="height:14.2pt; vertical-align:top; width:269.35pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">اللزوجة (مللي باسكال في الثانية / سنتيبواز)</p></td><td style="height:14.2pt; vertical-align:top; width:120.5pt"><p dir="RTL" style="margin-left:67.4pt; margin-right:.05in; text-align:justify">&nbsp;</p></td></tr><tr><td style="height:14.2pt; vertical-align:top; width:120.5pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">&nbsp;</p></td><td style="height:14.2pt; vertical-align:top; width:148.85pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">عند 20 درجة مئوية</p></td><td style="height:14.2pt; vertical-align:top; width:120.5pt"><p dir="RTL" style="margin-left:67.4pt; margin-right:.05in; text-align:justify">22.0</p></td></tr><tr><td style="height:14.2pt; vertical-align:top; width:120.5pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">&nbsp;</p></td><td style="height:14.2pt; vertical-align:top; width:148.85pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">عند 37 درجة مئوية</p></td><td style="height:14.2pt; vertical-align:top; width:120.5pt"><p dir="RTL" style="margin-left:67.4pt; margin-right:.05in; text-align:justify">10.0</p></td></tr><tr><td colspan="2" style="height:14.2pt; vertical-align:top; width:269.35pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">الضغط التناضحي عند 37 درجة مئوية</p></td><td style="height:14.2pt; vertical-align:top; width:120.5pt"><p dir="RTL" style="margin-left:67.4pt; margin-right:.05in; text-align:justify">&nbsp;</p></td></tr><tr><td style="height:14.2pt; vertical-align:top; width:120.5pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="height:14.2pt; vertical-align:top; width:148.85pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">(ميجاباسكال)</p></td><td style="height:14.2pt; vertical-align:top; width:120.5pt"><p dir="RTL" style="margin-left:67.4pt; margin-right:.05in; text-align:justify">2.02</p></td></tr><tr><td style="height:14.2pt; vertical-align:top; width:120.5pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="height:14.2pt; vertical-align:top; width:148.85pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">(الغلاف الجوي)</p></td><td style="height:14.2pt; vertical-align:top; width:120.5pt"><p dir="RTL" style="margin-left:67.4pt; margin-right:.05in; text-align:justify">19.9</p></td></tr><tr><td colspan="2" style="height:14.2pt; vertical-align:top; width:269.35pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">الأسمولية عند 37 درجة مئوية (الأسمولات المذابة في كل كيلوجرام من الماء)</p></td><td style="height:14.2pt; vertical-align:top; width:120.5pt"><p dir="RTL" style="margin-left:67.4pt; margin-right:.05in; text-align:justify">0.77</p></td></tr><tr><td colspan="2" style="height:14.2pt; vertical-align:top; width:269.35pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">الأسمولية عند 37 درجة مئوية (الأسمولات المذابة في كل لتر من المحلول)</p></td><td style="height:14.2pt; vertical-align:top; width:120.5pt"><p dir="RTL" style="margin-left:67.4pt; margin-right:.05in; text-align:justify">0.49</p></td></tr><tr><td colspan="2" style="height:14.2pt; vertical-align:top; width:269.35pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">الكثافة (جرام/مل)</p></td><td style="height:14.2pt; vertical-align:top; width:120.5pt"><p dir="RTL" style="margin-left:67.4pt; margin-right:.05in; text-align:justify">&nbsp;</p></td></tr><tr><td colspan="2" style="height:14.2pt; vertical-align:top; width:269.35pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">عند 20 درجة مئوية</p></td><td style="height:14.2pt; vertical-align:top; width:120.5pt"><p dir="RTL" style="margin-left:67.4pt; margin-right:.05in; text-align:justify">1.409</p></td></tr><tr><td colspan="2" style="height:14.2pt; vertical-align:top; width:269.35pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">عند 37 درجة مئوية</p></td><td style="height:14.2pt; vertical-align:top; width:120.5pt"><p dir="RTL" style="margin-left:67.4pt; margin-right:.05in; text-align:justify">1.399</p></td></tr><tr><td colspan="2" style="height:14.2pt; vertical-align:top; width:269.35pt"><p dir="RTL" style="margin-left:0in; margin-right:.05in; text-align:justify">الوزن الجزيئي للأيوبرومايد (جرام/مول)</p></td><td style="height:14.2pt; vertical-align:top; width:120.5pt"><p dir="RTL" style="margin-left:67.4pt; margin-right:.05in; text-align:justify">791.12</p></td></tr></tbody></table><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">يتوفر اولترافيست-370 في أحجام العبوات التالية:</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">10 زجاجات، تحتوي كل منها على 50 أو 100 مل</p><p dir="RTL" style="margin-left:0in; margin-right:0in; text-align:right">قد لا تُطرح جميع أحجام العبوات في السوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">الشركة المصنعة</p><p dir="RTL">باير إيه جي، مولرستراس 178،</p><p dir="RTL">13353 برلين، ألمانيا.</p><p dir="RTL" style="text-align:right">صاحب توكيل التسويق:</p><p dir="RTL">باير إيه جي، 51368 ليفركوزن، ألمانيا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            روجعت هذه النشرة آخر مرة في يوليو 2021.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ultravist®-150, 150 mg iodine/mL, solution for injection
Ultravist®-240, 240 mg iodine/mL, solution for injection or infusion
Ultravist®-300, 300 mg iodine/mL, solution for injection or infusion, or oral solution
Ultravist®-370, 370 mg iodine/mL, solution for injection or infusion, or oral solution

Iopromide

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ultravist-150:
1 mL solution for injection contains:
312 mg iopromide (equivalent to 150 mg bound iodine).

Ultravist-240:
1 mL solution for injection or infusion contains:
499 mg iopromide (equivalent to 240 mg bound iodine).

Ultravist-300:
1 mL solution for injection or infusion, or oral solution contains:
623 mg iopromide (equivalent to 300 mg bound iodine).

Ultravist-370:
1 mL solution for injection or infusion, or oral solution contains:
769 mg iopromide (equivalent to 370 mg bound iodine).

For the full list of excipients, see section 6.1.

Ultravist-	150	240	300	370
Iopromide concentration (mg/mL)	312	499	623	769
Iopromide content (g) in				
Vial containing:				
10 mL	–	–	6.2	–
Bottle containing
50 mL	
15.6	
24.9	
31.2	
38.4
75 mL	–	–	46.8	–
100 mL	–	–	62.3	76.9
150 mL	–	–	93.5	–
200 mL	–	–	124.6	153.8
500 mL	–	–	311.5	384.5
Prefilled plastic cartridge containing				
75 mL	–	–	46.8	57.7
100 mL	–	–	62.3	76.9
125 mL	–	–	77.9	96.1
150 mL	–	–	93.5	115.4

Ultravist-	150	240	300	370
Iodine concentration (mg/mL)	150	240	300	370
Iodine content (g) in				
Vial containing:				
10 mL	–	–	3.0	–
Bottle containing
50 mL	
7.5	
12.0	
15.0	
18.5
75 mL	–	–	22.5	–
100 mL	–	–	30.0	37.0
150 mL	–	–	45.0	–
200 mL	–	–	60.0	74.0
500 mL	–	–	150.0	185.0
Prefilled plastic cartridge containing				
75 mL	–	–	22.5	27.8
100 mL	–	–	30.0	37.0
125 mL	–	–	37.5	46.3
150 mL	–	–	45.0	55.5


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ultravist -150: solution for injection
Ultravist -240: solution for injection or infusion
Ultravist -300, -370: solution for injection or infusion, or oral solution

Clear, colourless to pale yellowish, particle-free solution.

Physico-chemical and physical properties:

Ultravist-	150	240	300	370
pH	6.5 - 8.0	6.5 - 8.0	6.5 - 8.0	6.5 - 8.0
Viscosity (mPa·s or cP)				
	at 20°C	2.3	4.9	8.9	22.0
	at 37°C	1.5	2.8	4.7	10.0
Osmotic pressure at 37°C				
		(MPa)	0.86	1.22	1.59	2.02
		(atm)	8.5	12.1	15.7	19.9
Osmolality at 37°C				
		(Osm/kg H2O)	0.33	0.48	0.59	0.77
Osmolarity at 37°C				
		(Osm/l sol.)	0.28	0.36	0.43	0.49
Density (g/mL)					
	at 20°C	1.164	1.263	1.328	1.409
	at 37°C	1.158	1.255	1.322	1.399
Molecular weight (g/mol)	791.12


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product is for diagnostic use only.</p><p>&nbsp;</p><p>Ultravist-150<em>:</em></p><p style="margin-left:28.35pt; text-indent:-28.35pt"><!--[if !supportLists]-->&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->For intraarterial digital subtraction angiography</p><p style="margin-left:28.35pt; text-indent:-28.35pt"><!--[if !supportLists]-->&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->To check for proper functioning of a dialysis shunt</p><p>&nbsp;</p><p style="margin-left:0in">Ultravist-240, -300, -370:</p><p style="margin-left:28.35pt; text-indent:-28.35pt"><!--[if !supportLists]-->&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Angiography, angiocardiography, digital subtraction angiography</p><p style="margin-left:28.35pt; text-indent:-28.35pt"><!--[if !supportLists]-->&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Contrast enhancement in computerised tomography</p><p style="margin-left:28.35pt; text-indent:-28.35pt"><!--[if !supportLists]-->&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Urography</p><p style="margin-left:28.35pt; text-indent:-28.35pt"><!--[if !supportLists]-->&ndash;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Visualization of body cavities</p><p style="margin-left:28.35pt; text-indent:-28.35pt">(Exception: myelography, ventriculography, cisternography)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:28.35pt; text-indent:-28.35pt"><u>General information</u></p><p style="margin-left:0in">The dose needs to be adjusted in accordance with the patient&#39;s age, weight, cardiac and renal function, general condition, pertinent clinical question, as well as the employed examination technique and area to be examined.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">The physician determines the suitable iodine concentration and required volume on a patient-by-patient basis. An overview of the recommended volumes for the various concentrations of iopromide solutions for each body region to be visualized is provided in tabular form at the end of this section.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">The total allowed dose of 1.5&nbsp;g iodine per kg of body weight should not be exceeded on any given examination day. For Ultravist-150, this corresponds to a volume of 10&nbsp;mL per kg of body weight, for Ultravist-240&nbsp;to a volume of 6.25&nbsp;mL per kg of body weight, for Ultravist-300&nbsp;to a volume of 5&nbsp;mL per kg of body weight, and for Ultravist-370&nbsp;to a volume of approximately 4&nbsp;mL per kg of body weight.</p><p>&nbsp;</p><p>As a rule, patients receiving contrast media intravascularly should remain in a reclining position during the administration procedure.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in"><em>Heating the contrast medium prior to application</em></p><p style="margin-left:0in">Contrast media that are heated to body temperature prior to application are more well tolerated and are easier to inject due to the lower viscosity.</p><p style="margin-left:0in"><em>&nbsp;</em></p><p style="margin-left:0in"><em>For further important information on handling see section&nbsp;6.6</em>.</p><p><strong>&nbsp;</strong></p><p><u>Type of application:</u></p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">Ultravist-150: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for intravascular use.</p><p style="margin-left:0in">Ultravist-240: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for intravascular or intracavitary use.</p><p style="margin-left:0in">Ultravist-300, Ultravist-370: &nbsp;&nbsp;&nbsp;&nbsp; for intravascular, intracavitary or oral use.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in"><u>The information below applies for the following individual application areas</u></p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in"><em>Intravenous urography</em></p><p style="margin-left:0in">It is important to note that when conducting intravenous urography in children, relatively high doses of contrast medium are required due to the poor physiological concentrating ability of the immature nephron of the infantile kidney.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in"><em>Computerised tomography (CT)</em></p><p style="margin-left:0in">Ultravist-300&nbsp;should be administered as a rapid intravenous injection, and if possible, via a high pressure injector. When slow scanners are used, to achieve relatively constant blood levels we recommend that half of the dose be administered as a bolus and the remainder of the dose then given within 2-6&nbsp;minutes, even if a steady peak cannot be maintained. The scan process is to be started after completion of the initial administration phase.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">When performing spiral CT, and in particular when using multi-slice techniques, a variety of data are compiled while the patient during the breath-holding phase. In order to optimize the effect of the intravenous bolus injection in the region under examination (optimal uptake is achieved at different times in the variously, pathologically altered tissues), the use of an automatic high-pressure injector and bolus is recommended.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">When performing CT, the required quantity of contrast medium and administration rate are determined in relation to the organs to be examined, the diagnostic question at hand, but also in consideration of the apparatus actually available for the specific examination (e.g. scan and image forming times). Infusion is recommended when using slow-working devices, and bolus injection for fast scanners.</p><p>&nbsp;</p><p><em>Digital subtraction angiography (DSA)</em></p><p style="margin-left:0in">In many cases, intraarterial DSA is able to produce strongly enhanced images of the great vessels and arteries of the neck, kidney and limbs, even in cases where the applied concentration of iopromide solution (Ultravist-150, -240, -300&nbsp;or -370) would be insufficient for conventional angiography. This method is thus recommended for patients with impaired renal function.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">To ensure sufficiently contrasted visualization of the arteries, e.g. throat, head, kidney and extremity regions, 10&nbsp;-&nbsp;40&nbsp;mL Ultravist-150&nbsp;are generally applied directly or injected via a catheter, depending on the size of the vessel.</p><p>&nbsp;</p><p>When performing arteriography of the lower extremities, in certain cases it may be necessary to apply higher quantities of contrast media (ca. 200&nbsp;mL), e.g. when both legs need to be examined (see table).</p><p>&nbsp;</p><p><em>Dialysis shunt</em></p><p>Ultravist-150&nbsp;is suited to visualising a dialysis shunt for the purpose of checking that it is functioning properly, for which 3&nbsp;-&nbsp;5&nbsp;mL Ultravist-150&nbsp;are administered via a single injection. Not more than 50&nbsp;mL contrast medium is required for the entire procedure of visualising the immediate shunt vessel and venous drainage as far as the <em>V.&nbsp;cava superior</em>.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in"><em>Visualization of body cavities</em></p><p style="margin-left:0in">The contrast medium should be injected under fluoroscopic monitoring when administered in the context of arthrography, hysterosalpingography and ERCP (endoscopic retrograde cholangiopancreatography).</p><p><strong>&nbsp;</strong></p><p><u>Additional information regarding special patient groups</u></p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in"><em>Neonates and babies</em></p><p style="margin-left:0in">Babies under the age of one&nbsp;year ─ particularly neonates ─ are susceptible to an electrolyte imbalance and haemodynamic changes. Caution is therefore required in selecting the dose of contrast medium, conducting the examination, in addition to considering the specific health status of the patient.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in"><em>Patients with impaired renal function</em></p><p style="margin-left:0in">Since iopromide is nearly exclusively excreted via the kidneys in unchanged form, it takes longer for iopromide to be eliminated from patients with impaired renal function. In order to reduce the risk of contrast-medium-induced kidney injury, patients with pre-existing renal function impairment should receive the lowest possible dose of contrast medium (cf. sections&nbsp;4.4 and 5.2). For such patients, it is also recommended to monitor renal function for at least three days after the examination.</p><p>&nbsp;</p><p>Table: Overview of the areas of application of various concentrations of iopromide solutions in X-ray diagnostics given via injection, infusion or oral administration &ndash; the recommended solutions are shown in bold print:</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" border="1" style="width:624px"><tbody><tr><td rowspan="2" style="background-color:#cccccc; width:184.3pt">&nbsp;<p><strong>Area of application</strong></p></td><td rowspan="2" style="width:99.2pt"><p style="margin-left:.05in"><strong>Concentration of bound iodine (mg/mL)</strong></p></td><td colspan="2" style="vertical-align:top; width:184.3pt"><p style="margin-left:.05in">Volume (mL)</p></td></tr><tr><td style="width:92.15pt"><p style="margin-left:.05in"><strong>Conventional film-angiography</strong></p></td><td style="width:92.15pt"><p style="margin-left:.05in">Digital subtraction angiography</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p><strong>Cerebral angiography</strong></p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp;</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp;</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Aortic arch</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>300</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">50&nbsp;-&nbsp;80</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">25&nbsp;-&nbsp;40</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">370</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">40&nbsp;-&nbsp;60</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">25&nbsp;-&nbsp;30</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>A. carotis communis</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>300</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">10&nbsp;-&nbsp;12</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp; 6&nbsp;-&nbsp;8</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>A. carotis externa</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>300</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp; 4&nbsp;-&nbsp;8</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp; 4&nbsp;-&nbsp;6</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>A. vertebralis</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>300</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp; 4&nbsp;-&nbsp;8</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp; 4&nbsp;-&nbsp;6</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p><strong>Thoracic angiography</strong></p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp;</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp;</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Aorta</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>300</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">50&nbsp;-&nbsp;70</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">30&nbsp;-&nbsp;50</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">370</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">50&nbsp;-&nbsp;60</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">25&nbsp;-&nbsp;30</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p><strong>Abdominal angiography</strong></p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp;</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp;</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Aorta</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>300</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">50&nbsp;-&nbsp;80</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">25&nbsp;-&nbsp;35</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">370</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">40&nbsp;-&nbsp;60</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">20&nbsp;-&nbsp;25</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>A. coeliaca</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>300</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">25&nbsp;-&nbsp;35</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">15&nbsp;-&nbsp;20</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>A. mesenterica superior</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>300</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">30&nbsp;-&nbsp;40</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">15&nbsp;-&nbsp;20</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>A. mesenterica inferior</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>300</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">15&nbsp;-&nbsp;25</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp; 8&nbsp;-&nbsp;12</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>A. splenica</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>300</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">15&nbsp;-&nbsp;30</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp; 8&nbsp;-&nbsp;15</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>A. hepatica</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>300</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">20&nbsp;-&nbsp;40</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">10&nbsp;-&nbsp;20</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>A. renalis</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>300</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">8&nbsp;-&nbsp;15</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp; 5&nbsp;-&nbsp;8</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p><strong>Angiography of the extremities</strong></p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">&nbsp;</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp;</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp;</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p><em>Upper extremities</em></p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">&nbsp;</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp;</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp;</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Arteriography</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>150</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in; margin-right:17.75pt; text-align:center">-</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">10&nbsp;-&nbsp;40</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>300</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">20&nbsp;-&nbsp;30</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">10&nbsp;-&nbsp;15</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Phlebography</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>240</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">30&nbsp;-&nbsp;40</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">10&nbsp;-&nbsp;15</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">300</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">20&nbsp;-&nbsp;30</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp; 8&nbsp;-&nbsp;15</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Visualization of dialysis shunt</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>150</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp; 3&nbsp;-&nbsp;50</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp; 3&nbsp;-&nbsp;50</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p><em>Lower extremities</em></p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">&nbsp;</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp;</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp;</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Pelvis-leg arteriography</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>150</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in; margin-right:17.75pt; text-align:center">-</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">~ 100</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">300</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">70&nbsp;-&nbsp;150</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">40&nbsp;-&nbsp;80</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">370</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">60&nbsp;-&nbsp;120</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">40&nbsp;-&nbsp;70</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p><em>A. femoralis</em></p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>300</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">20&nbsp;-&nbsp;30</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">10&nbsp;-&nbsp;15</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Phlebography</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>240</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">80&nbsp;-&nbsp;100</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">60&nbsp;-&nbsp;80</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">300</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">60&nbsp;-&nbsp;80</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">60&nbsp;-&nbsp;80</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p><strong>Angiocardiography</strong></p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">&nbsp;</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp;</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp;</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Ventricles</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>370</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">40&nbsp;-&nbsp;60</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">20&nbsp;-&nbsp;30</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p><em>A. coronaria sinistra</em></p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>370</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">6&nbsp;-&nbsp;10</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp; 4&nbsp;-&nbsp;5</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p><em>A. coronaria dextra</em></p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>370</strong></p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">4&nbsp;-&nbsp;8</p></td><td style="vertical-align:top; width:92.15pt"><p style="margin-left:.05in">&nbsp; 4&nbsp;-&nbsp;5</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p><strong>Computerised tomography</strong></p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">&nbsp;</p></td><td colspan="2" style="vertical-align:top; width:184.3pt"><p style="margin-left:.05in">&nbsp;</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Head &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adults</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">240<strong>/300/370</strong></p></td><td colspan="2" style="vertical-align:top; width:184.3pt"><p style="margin-left:.05in">100</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; children</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">240<strong>/300</strong></p></td><td colspan="2" style="vertical-align:top; width:184.3pt"><p style="margin-left:.05in">2.0&nbsp;mL/kg body weight</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Whole-body &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adults</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">240/<strong>300/370</strong></p></td><td colspan="2" style="vertical-align:top; width:184.3pt"><p style="margin-left:.05in">100&nbsp;-&nbsp;150</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; children</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">240/<strong>300</strong></p></td><td colspan="2" style="vertical-align:top; width:184.3pt"><p style="margin-left:.05in">1.0&nbsp;-&nbsp;3.0&nbsp;mL/kg body weight</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p><strong>Intravenous urography</strong></p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">&nbsp;</p></td><td colspan="2" style="vertical-align:top; width:184.3pt"><p style="margin-left:.05in">&nbsp;</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Adults</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">240/<strong>300/</strong>370</p></td><td colspan="2" style="vertical-align:top; width:184.3pt"><p style="margin-left:.05in">1&nbsp;-&nbsp;1.5&nbsp;mL/kg body weight</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Neonates&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;&nbsp;&nbsp; 5&nbsp;kg</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">240/<strong>300/</strong>370</p></td><td colspan="2" style="vertical-align:top; width:184.3pt"><p style="margin-left:.05in">4&nbsp;&nbsp;&nbsp; mL/kg body weight</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Babies&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5&nbsp;&lt;&nbsp;10&nbsp;kg</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">240/<strong>300/</strong>370</p></td><td colspan="2" style="vertical-align:top; width:184.3pt"><p style="margin-left:.05in">3&nbsp;&nbsp;&nbsp; mL/kg body weight</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Small children&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10&nbsp;&lt;&nbsp;30&nbsp;kg</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">240/<strong>300/</strong>370</p></td><td colspan="2" style="vertical-align:top; width:184.3pt"><p style="margin-left:.05in">2&nbsp;&nbsp;&nbsp; mL/kg body weight</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>School children&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &gt;&nbsp;30&nbsp;kg</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">240/<strong>300/</strong>370</p></td><td colspan="2" style="vertical-align:top; width:184.3pt"><p style="margin-left:.05in">1.5&nbsp;mL/kg body weight</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p><strong>Body cavities</strong></p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">&nbsp;</p></td><td colspan="2" style="vertical-align:top; width:184.3pt"><p style="margin-left:.05in">&nbsp;</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Arthrography</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>240/300</strong>/370</p></td><td colspan="2" style="vertical-align:top; width:184.3pt"><p style="margin-left:.05in">&nbsp; 2&nbsp;-&nbsp;15</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Hysterosalpingography</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>240/300</strong>/370</p></td><td colspan="2" style="vertical-align:top; width:184.3pt"><p style="margin-left:.05in">10&nbsp;-&nbsp;25</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Fistulography</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in">240/<strong>300</strong>/370</p></td><td colspan="2" style="vertical-align:top; width:184.3pt"><p style="margin-left:.05in">&nbsp; 1&nbsp;-&nbsp;10</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>ERCP</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>240/300</strong>/370</p></td><td colspan="2" style="vertical-align:top; width:184.3pt"><p style="margin-left:.05in">10&nbsp;-&nbsp;30</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Galactography</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>240/300</strong>/370</p></td><td colspan="2" style="vertical-align:top; width:184.3pt"><p style="margin-left:.05in">&nbsp; 1&nbsp;-&nbsp;&nbsp; 3</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Oesophagus-stomach-intestines</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 300/370</strong></p></td><td colspan="2" style="vertical-align:top; width:184.3pt"><p style="margin-left:.05in">10&nbsp;-&nbsp;100</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Ureterography, retrograde urography,</p><p>urethrography, pyelography</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>&nbsp;</strong></p><p style="margin-left:.05in"><strong>240/300</strong>/370</p></td><td colspan="2" style="vertical-align:top; width:184.3pt"><p style="margin-left:.05in">&nbsp;</p><p style="margin-left:.05in">&nbsp; 2&nbsp;-&nbsp;&nbsp; 20</p></td></tr><tr><td style="background-color:#cccccc; width:184.3pt"><p>Micturitional cystography</p></td><td style="vertical-align:top; width:99.2pt"><p style="margin-left:.05in"><strong>240/300</strong>/370</p></td><td colspan="2" style="vertical-align:top; width:184.3pt"><p style="margin-left:.05in">250&nbsp;-&nbsp;500</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity (allergy) to the active substance or iodine or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>For all types of administration</u></p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in"><em>Allergoid or anaphylactoid reactions (hypersensitivity reactions)</em></p><p style="margin-left:0in; text-align:left">After administration of Ultravist, dose-independent pseudo-allergic (allergoid)/hypersensitivity reactions or other idiosyncratic reactions (cardiovascular, respiratory and cutaneous reactions) reactions can occur. Pseudo-allergic reactions in varying severities and even shock are possible (also see section&nbsp;4.8). Most of these reactions occur within one half hour of contrast media administration, but delayed reactions are also possible (after hours or days).</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">The risk of hypersensitivity reactions increases in case of:</p><p style="margin-left:28.35pt; text-align:left; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->history of reaction to contrast media</p><p style="margin-left:28.35pt; text-align:left; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->known bronchial asthma or other predisposition to allergies</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">At the beginning of every contrast media examination, patients should thus be extensively queried about their medical histories in terms of the abovementioned risk factors. The indication must be determined within strict boundaries for patients with allergic diathesis, due to the greater risk of hypersensitivity reactions (including severe reactions).</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">Due to their irregular occurrence, such events are not predictable in specific cases.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Patients treated with beta-blockers may experience stronger hypersensitivity reactions, particularly when bronchial asthma is involved.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">Furthermore, patients who experience hypersensitivity reactions who are also taking beta-blockers may be refractory to standard treatment with beta agonists.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">Patients with cardiovascular diseases who experience a severe hypersensitivity reaction are at a higher risk for serious or even fatal outcomes.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">In such cases, i.e. patients with an increased risk for allergoid reactions, patients who have already experienced moderate to severe acute reactions, patients with asthma or allergies requiring medicinal treatment ─ the advisability of pre-medication with corticoids should be considered prior to the contrast media examination.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in"><em>Preparing for an emergency situation</em></p><p style="margin-left:0in">Irrespective of the quantity and type of administration, even mild allergoid symptoms may be the first signs of a serious anaphylactoid reaction requiring treatment. For this reason, iodinated contrast media should only be employed in medical environments where emergency treatment is available, i.e. the necessary equipment and medications, physicians with sufficient clinical experience, as well as trained assisting medical staff.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">It must therefore be possible to initiate immediate emergency measures for all patients in order to treat a serious reaction, and to maintain direct access to the requisite emergency drugs and emergency surgical kit.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">The patient should be observed for at least &frac12;&nbsp;hour after the end of administration, as experience shows that the majority of all serious incidents occur within this time period.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in"><em>Severe cutaneous adverse reactions (SCARs)</em></p><p style="margin-left:0in">Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalised exanthematous pustulosis (AGEP), which can be life-threatening of fatal,&nbsp; exfoliative dermatitis, Stevens-Johnson syndrome (SJS), have been reported with unknown frequency in association with iopromide administration.</p><p>&nbsp;</p><p style="margin-left:0in">&nbsp;Patients should be advised of the signs and symptoms and monitored closely for skin reactions.</p><p style="margin-left:0in">&nbsp;</p><p>In children, the initial presentation of a rash can be mistaken for an infection, and physicians should consider the possibility of a reaction to iopromide in children that develop signs of rash and fever.</p><p>&nbsp;</p><p>Most of these reactions occurred within 8 weeks (AGEP 1-12 days, DRESS 2-8 weeks, SJS/TEN 5&nbsp;days up to 8&nbsp;weeks).</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">If the patient has developed a serious reaction such as SJS, TEN, AGEP or DRESS with the use of iopromide, iopromide must not be readministered in this patient at any time.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in"><em>Thyroid dysfunction</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">Iodinated X-ray contrast media influence thyroid function because of the free iodide contained in the solutions, in addition to the additional iodide released within the body after administration due to de-iodination.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">A particularly careful risk-benefit assessment is required for patients with known or suspected hyperthyroidism or for patients with nodular goitre, because iodated contrast media may induce hyperthyroidism and thyrotoxic crisis in such patients. Thyroid function status must therefore be clarified prior to using Ultravist. Preventative thyrostatic medication can be considered for patients with known or suspected hyperthyroidism.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">There have been reports of thyroid function test results indicative of hypothyroidism or transient thyroid suppression after administration of iodinated contrast media in adults and paediatric patients. Prior to use of iodinated contrast media, consideration should be given to the potential risk of hypothyroidism in patients with known or suspected thyroid dysfunction.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p><em>Thyroid Dysfunction in Pediatric Patients 0 to 3 Years of Age</em></p><p>Thyroid dysfunction characterized by hypothyroidism or transient thyroid suppression has been reported after both single exposure and multiple exposures to iodinated contrast media. Among patients 0 to 3 years of age exposed to iodinated contrast media, thyroid dysfunction has been reported in 1% to 15% depending on the age of the patient and the dose of the iodinated contrast agent.</p><p>Younger age, very low birth weight, prematurity, and the presence of other conditions, such as, admission to neonatal or pediatric intensive care units, and cardiac conditions are associated with an increased risk. Pediatric patients with cardiac conditions may be at the greatest risk given that they often require high doses of contrast during invasive cardiac procedures, such as catheterization and computed tomography (CT).</p><p>Pediatric patients 0 to 3 years of age warrant closer monitoring because an underactive thyroid during early life may be harmful for motor, hearing, and cognitive development and may require transient T4 replacement therapy. Evaluate thyroid function in all pediatric patients 0 to 3 years of age within 3 weeks following exposure to iodinated contrast media, especially in term and preterm neonates. If thyroid dysfunction is detected, treat and monitor thyroid function as clinically needed.</p><p><em>CNS disorders</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">Patients with CNS disorders may be at increased risk to have neurological complications in relationship to iopromide administration. Neurological complications are more frequent in cerebral angiography and related procedures.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Encephalopathy has been reported with the use of iopromide (see section&nbsp;4.8). Contrast encephalopathy may manifest with symptoms and signs of neurological dysfunction such as headache, visual disturbance, cortical blindness, confusion, seizures, loss of coordination, hemiparesis, aphasia, unconsciousness, coma and cerebral oedema. Symptoms usually occur within minutes to hours after administration of iopromide and generally resolve within days.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Factors which increase blood-brain barrier permeability facilitate the passage of the contrast medium into cerebral tissue, possibly leading to CNS reactions, for instance encephalopathy.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">If contrast encephalopathy is suspected, appropriate medical management should be initiated and administration of iopromide must not be repeated.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in"><em>Hydration</em></p><p style="margin-left:0in">Adequate hydration status must be ensured in all patients prior to the intravascular administration of Ultravist. This applies in particular to patients who are at an increased risk of contrast medium-associated acute kidney injury (PC-AKI) (see section&nbsp;4.4 &quot;Intravascular applications &ndash; Acute kidney injury&quot;) as well as to patients with polyuria, oliguria, neonates, babies, small children and older patients.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">Adequate hydration status can be achieved in most patients by oral fluid administration as needed.</p><p style="margin-left:0in">Prophylactic intravenous hydration should be considered, especially in patients at an increased risk of PC-AKI. The decision as to which patients require prophylactic intravenous hydration should be based on recommendations from the most recent and evidence-based clinical guidelines and the individual benefit-risk ratio. This should include consideration of the dose applied (e.g. high dose), route of administration (&#39;first pass&#39; exposure) and renal function (presence of severe renal failure). The presence of concomitant diseases should be considered. In the event of concomitant cardiac disease (e.g. advanced heart failure), prophylactic intravenous hydration may lead to serious cardiac complications (also see sections&nbsp;4.4 &quot;Intravascular applications - Acute kidney injury&quot;, &quot;Intravascular applications - Cardiovascular disease&quot; and section&nbsp;4.8 &quot;Tabulation of adverse reactions&quot;).</p><p style="margin-left:0in">&nbsp;</p><p><em>Anxiety</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">Conditions involving over-excitement, anxiety and pain can increase the risk of side effects or contrast-media-related reactions. Care should be taken to minimise any anxiety-promoting conditions.</p><p>&nbsp;</p><p><em>Pre-testing</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">Pre-testing for hypersensitivity with a low test dose of contrast medium is not recommended, inasmuch as this approach has no predictive value, and on occasion, has even led to serious, and at times even lethal hypersensitivity reactions.</p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>&nbsp;</strong></p><p><u>Intravascular applications</u></p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in"><em>Cardiovascular diseases</em></p><p>Patients with serious cardiovascular diseases or severe coronary heart disease are at a higher risk for clinically relevant haemodynamic changes and arrhythmia.</p><p>&nbsp;</p><p>This applies particularly after intracoronary, left ventricular and right ventricular administration of contrast media (cf. section&nbsp;4.8).</p><p>&nbsp;</p><p>Patients particularly predisposed to cardiac reactions are those with heart failure, severe coronary heart disease, unstable angina pectoris, heart valve diseases, recent cardiac infarction, with coronary bypasses and patients with pulmonary hypertension.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">Intravascular injection of Ultravist<sup> </sup>can cause pulmonary oedema in patients with cardiac insufficiency.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left"><em>Acute kidney injury</em></p><p style="margin-left:0in; text-align:left">Contrast medium-associated acute kidney injury (PC-AKI) may occur after the intravascular contrast medium administration of Ultravist; this can manifest as a transient impairment of renal function or even acute renal failure in rare instances.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">Predisposing factors include: existing renal insufficiency (also see section&nbsp;4.2 &ldquo;Additional information regarding special patient groups &ndash; Patients with impaired renal function&rdquo;), dehydration (also see section&nbsp;4.4 &ldquo;All types of administration &ndash; Hydration&rdquo;, diabetes mellitus, multiple myeloma/paraproteinaemia, high doses of contrast media and/or multiple injections of Ultravist.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in">Patients with moderately to severely (eGFR 44-30&nbsp;ml/min/1.73m<sup>2</sup>) impaired renal function are at an increased risk of PC-AKI in the event of intra-arterial contrast medium administration and &quot;first-pass&quot; renal exposure (e.g. direct contrast medium administration into the renal artery, thoracic and suprarenal abdominal aorta).</p><p style="margin-left:0in; text-align:left">Patients with severely impaired renal function (eGFR &lt;30&nbsp;ml/min/1.73m<sup>2</sup>) are at an increased risk of PC-AKI in the event of intravenous or intra-arterial contrast medium administration with &quot;second-pass&quot; renal exposure (e.g. after injection into the right heart, pulmonary artery, carotid artery, subclavian artery, coronary artery, mesenteric artery or infrarenal arteries) (also see section&nbsp;4.4 &quot;All types of administration - Hydration&quot;).</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">Intravascular Ultravist<sup> </sup>can be used in patients without residual renal function who require dialysis, because iodine-containing contrast media can be eliminated via dialysis. Haemodialysis should be conducted immediately after the radiological examination.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">In case of severe renal failure, any additional severe impairment of the liver can result in seriously delayed excretion of the contrast medium, which may require haemodialysis.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left"><em>Diabetes mellitus</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">To avoid lactic acidosis, patients with diabetes mellitus receiving metformin treatment should have their serum creatinine levels measured before receiving an intravascular administration of an iodinated contrast medium (see section&nbsp;4.5).</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Based on the results of the renal function test, the discontinuation of existing metformin therapy should be considered.</p><p>&nbsp;</p><p>For <em><u>emergency patients</u></em> and in case of restricted or unknown renal function, physicians must carefully assess the risks versus the benefits of a contrast-enhanced examination and must take the necessary precautions by: discontinuing metformin therapy, hydrating the patient, monitoring renal function values, serum lactate and pH and closely monitoring the patient for any clinical signs of lactic acidosis.</p><p>&nbsp;</p><p><em>Thromboembolic events</em></p><p>One property of non-ionic contrast media is their low interference with normal physiological functions. It follows that <em>in vitro</em>, non-ionic contrast media is distinguished by a weaker anticoagulant effect, than is ionic contrast media.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">In addition to the contrast medium itself, numerous other factors can contribute to the onset of thromboembolic events. These factors include: the duration of the examination procedure, number of injections, type of catheter/syringe materials, underlying diseases and concomitant medications. This needs to be taken into account in the context of vessel catheterisation to minimise the examination-related risk of embolism and thrombosis. In particular, careful angiographic techniques must be used, the catheter should be flushed frequently with physiological saline solution (if possible with heparin), and the overall duration of the procedure needs to be kept to a minimum.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left"><em>CNS disorders</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">Caution should be exercised with respect to intravascular administration in patients with acute cerebral infarction or acute intracranial haemorrhage, in patients with diseases that can impair the blood-brain barrier, as well as in patients with cerebral oedema or acute demyelinisation. After contrast medium administration, the incidence of cerebral seizures may increase in patients with intracranial tumours, metastases or epilepsy. Neurological symptoms arising from cerebrovascular disorders, intracranial tumours or metastases, degenerative or inflammatory processes can be exacerbated by intraarterial contrast media administration. Intraarterial contrast media injection can trigger vasospasms and subsequent cerebral ischemic phenomena. Patients with symptomatic cerebrovascular disorders, recent stroke or frequent transient ischaemic attacks are at greater risk of suffering contrast-media-induced neurological complications.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">It is recommended that anticonvulsive therapy be kept close at hand for emergency use.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in"><em>Further risk factors</em></p><p style="margin-left:0in; text-align:left">Patients with <u>phaeochromocytoma</u> are at higher risk for developing a hypertensive crisis after intravascular contrast medium administration.</p><p>&nbsp;</p><p>Ultravist may exacerbate the symptoms of <u>myasthenia gravis</u>.</p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>&nbsp;</strong></p><p><strong>Use in body cavities</strong></p><p style="margin-left:0in; margin-right:0in; text-align:left"><strong>&nbsp;</strong></p><p style="margin-left:0in">For patients with acute pancreatitis and acute cholangitis, ERCP with Ultravist should not be conducted until the risks and benefits are carefully assessed. The procedure must be postponed until any acute symptoms have subsided (3-4&nbsp;weeks), unless immediate therapeutic measures such as the removal of an obstructive concrement or stenosis bypass are required.</p><p style="margin-left:0in">&nbsp;</p><p><strong>Information about excipients</strong></p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose (based on the average amount for a person weighing 70&nbsp;kg), that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Biguanides (metformin):</u> Biguanides may be eliminated in a delayed fashion in patients suffering from acute renal failure or serious chronic kidney disease, which can subsequently accumulate, thereby possibly causing lactic acidosis.</p><p>&nbsp;</p><p>Because Ultravist use can lead to impaired renal function or can exacerbate a renal function disorder, patients treated with metformin may be at an increased risk for developing lactic acidosis, in particular, patients with a pre-existing renal function disorder (cf. section&nbsp;4.4 &ldquo;Intravascular applications &ndash; Acute kidney injury&rdquo;). Depending on renal function test results, the advisability of stopping metformin treatment should be carefully considered.</p><p><u>&nbsp;</u></p><p><u>Interleukin-2:</u> Previous treatment (up to several weeks) with interleukin-2&nbsp;has been linked to an increased risk for delayed onset of contrast media reactions in association with Ultravist use.</p><p><u>&nbsp;</u></p><p><u>Radioisotopes</u>: Following intravascular administration, iodine-containing contrast media can reduce the ability of thyroid tissue to absorb isotopes. As a consequence, the diagnosing and treatment of impaired thyroid gland function with thyrostatic radioisotopes may be impaired for several weeks after using Ultravist, and even longer in isolated cases.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in"><u>Pregnancy</u></p><p style="margin-left:0in">Suitable and well controlled studies in pregnant women have not been conducted.</p><p style="margin-left:0in">Experimental animal reproduction toxicity studies conducted during pregnancy have not shown any evidence of harmful effects in terms of embryo/foetal development, birth, or postnatal development, following iopromide use in man for diagnostic purposes.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">In humans, the safety of contrast media administration during pregnancy has not yet been sufficiently demonstrated. Since exposure to radiation during pregnancy must be avoided as far as possible, the benefits of any X-ray examination&nbsp;-&nbsp;with or without contrast media&nbsp;-&nbsp;must be carefully assessed. This risk-benefit assessment pertaining to the use of iodinated contrast media must also take the iodine sensitivity of the foetal thyroid into account.</p><p style="margin-left:0in"><strong>&nbsp;</strong></p><p style="margin-left:0in"><u>Breastfeeding</u></p><p style="margin-left:0in">The safety of Ultravist in breast-fed infants has not been studied. Only a very small portion of iodinated contrast medium passes into breast milk. No damage to the breast-fed infant is to be expected (cf. section&nbsp;4.4&nbsp;&quot;Thyroid dysfunction&quot;).</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">The free iodide contained in the contrast medium solution and the iodide additionally released in the body by way of deiodination accumulates to a higher degree in breast milk. In order to protect the breastfeeding baby from an overexposure to iodide (risk of blocking thyroid hormone synthesis), for safety reasons it is recommended that that the breastfeeding of babies of less than 4&nbsp;months of age be suspended for two&nbsp;days, and that any siphoned milk be discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies have been conducted as regards the effects on the ability to drive and to use machinery after using Ultravist.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety profile</u></p><p>The overall safety profile of Ultravist is based on data taken from clinical studies involving 3,900&nbsp;patients prior to market launch, and more than 74,000&nbsp;patients thereafter, in addition to data obtained from spontaneous reporting and literature sources.</p><p>&nbsp;</p><p>The most frequently occurring side effects observed in patients after Ultravist use (&ge;4%) are headache, nausea and vasodilatation.</p><p>&nbsp;</p><p>The most serious side effects observed in patients after Ultravist use are anaphylactoid shock, respiratory arrest, bronchospasm, laryngeal oedema, pharyngeal oedema, asthma, coma, cerebral infarction, stroke, cerebral oedema, cerebral seizures/convulsion, arrhythmia, cardiac arrest, myocardial ischemia, myocardial infarction, heart failure, bradycardia, cyanosis, low blood pressure, shock, dyspnoea, pulmonary oedema, respiratory insufficiency, and aspiration.</p><p>&nbsp;</p><p>Different kinds of side effects may occur in association with the use of iodine-containing contrast media. A differentiation is made between unpredictable pseudo-allergic reactions (cf. section 4.4), and pharmacologically explainable and predictable organotoxic reactions. Pseudo-allergic and organotoxic reactions can occur simultaneously, so that it is not always possible to definitively categorise the specific event.</p><p>&nbsp;</p><p><u>Tabular presentation of adverse events</u></p><p>Side effects observed after Ultravist use are listed in the table below and are categorised according to system organ class. The most suitable MedDRA term was chosen to describe a certain reaction, its synonyms and related symptoms.</p><p>&nbsp;</p><p>Side effects from clinical studies are classified according to their frequency of occurrence.</p><p>&nbsp;</p><p>The frequency of occurrence of undesirable effects is defined according to the following categories:</p><p style="margin-right:-7.15pt">&nbsp;</p><p style="margin-right:-7.15pt">Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge;1/100&nbsp;to &lt;1/10)<br />Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge;1/1,000&nbsp;to &lt;1/100)<br />Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge;1/10,000&nbsp;to &lt;1/1,000)<br />Unknown &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (frequency cannot be estimated on the basis of the available data)</p><p>&nbsp;</p><p>Side effects taken from post-marketing reporting and those for which no statement regarding frequency of occurrence can be made are listed under &quot;unknown&quot;.</p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" border="1" style="width:655px"><thead><tr><td style="vertical-align:top; width:89.4pt"><p><strong>System organ class</strong></p></td><td style="vertical-align:top; width:84.0pt"><p>Common</p></td><td style="vertical-align:top; width:102.0pt"><p>Uncommon</p></td><td style="vertical-align:top; width:84.0pt"><p>Rare</p></td><td style="vertical-align:top; width:132.0pt"><p>Unknown</p></td></tr></thead><tbody><tr><td style="vertical-align:top; width:89.4pt"><p>Immune system</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:102.0pt"><p>Hypersensitivity/anaphylactoid reactions</p><p>(anaphylactoid shock<sup>&sect;) *)</sup>,</p><p>Apnoea<sup>&sect;) *)</sup>,</p><p>Bronchospasm<sup>*)</sup>,</p><p>Laryngeal<sup>*)&nbsp;</sup>/<sup>&nbsp;</sup>Pharyngeal<sup>*)&nbsp;</sup>/<sup>&nbsp;</sup>Facial oedema,</p><p>Tongue oedema<sup>&sect;)</sup>,</p><p>Laryngeal <sup>&nbsp;</sup>/<sup>&nbsp;</sup>pharyngeal spasm<sup>&sect;)</sup>,</p><p>Asthma<sup>&sect;) *)</sup>,</p><p>Conjunctivitis<sup>&sect;)</sup>,</p><p>Lacrimation<sup>&sect;)</sup>,</p><p>Sneezing,</p><p>Coughing,</p><p>Mucosal oedema,</p><p>Rhinitis<sup>&sect;)</sup>,</p><p>Hoarseness<sup>&sect;)</sup>,</p><p>Throat irritation<sup>&sect;)</sup>,</p><p>Urticaria,</p><p>Pruritus,</p><p>Angioedema)</p><p>&nbsp;</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:132.0pt"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:89.4pt"><p>Endocrine diseases</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:102.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:132.0pt"><p>Thyrotoxic crisis,</p><p>Disturbed thyroid function</p></td></tr><tr><td style="vertical-align:top; width:89.4pt"><p>Psychiatric diseases</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:102.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:84.0pt"><p>Anxiety</p></td><td style="vertical-align:top; width:132.0pt"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:89.4pt"><p>Diseases of the nervous system</p></td><td style="vertical-align:top; width:84.0pt"><p>Dizziness,</p><p>Headache,</p><p>Dysgeusia</p></td><td style="vertical-align:top; width:102.0pt"><p>Vasovagal reactions,</p><p>Confusion,</p><p>Restlessness,</p><p>Paraesthesia/<br />hypaesthesia,</p><p>Somnolence</p><p>&nbsp;</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:132.0pt"><p>Coma<sup>*)</sup>.</p><p>Cerebral ischaemia/infarction<sup>*)</sup>,</p><p>Stroke<sup>*)</sup>,</p><p>Cerebral oedema<sup>a) *)</sup>,</p><p>Cerebral seizures/convulsions<sup>*)</sup>,</p><p>Temporary cortical blindness<sup>a)</sup>,</p><p>Unconsciousness,</p><p>Agitation,</p><p>Amnesia,</p><p>Tremor,</p><p>Speech disorders,</p><p>Paresis/paralysis,</p><p>Contrast encephalopathy</p></td></tr><tr><td style="vertical-align:top; width:89.4pt"><p>Eye diseases</p></td><td style="vertical-align:top; width:84.0pt"><p>Blurred vision/visual disturbance</p></td><td style="vertical-align:top; width:102.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:132.0pt"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:89.4pt"><p>Diseases of the ear and labyrinth</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:102.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:132.0pt"><p>Impaired hearing</p></td></tr><tr><td style="vertical-align:top; width:89.4pt"><p>Heart diseases</p></td><td style="vertical-align:top; width:84.0pt"><p>Chest pain/tightness in chest</p></td><td style="vertical-align:top; width:102.0pt"><p>Arrhythmias<sup>*)</sup></p></td><td style="vertical-align:top; width:84.0pt"><p>Cardiac arrest<sup>*)</sup>,</p><p>Myocardial ischaemia<sup>*)</sup>,</p><p>Palpitations</p></td><td style="vertical-align:top; width:132.0pt"><p>Myocardial infarction <sup>*)</sup>,</p><p>Heart failure <sup>*)</sup>,</p><p>Bradycardia <sup>*)</sup>,</p><p>Tachycardia,</p><p>Cyanosis<sup>*)</sup></p></td></tr><tr><td style="vertical-align:top; width:89.4pt"><p>Vascular diseases</p></td><td style="vertical-align:top; width:84.0pt"><p>Hypertension,</p><p>Vasodilatation</p></td><td style="vertical-align:top; width:102.0pt"><p>Hypotension<sup>*)</sup>,</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:132.0pt"><p>Shock<sup>*)</sup>,</p><p>Thromboembolic events<sup>a)</sup>,</p><p>Vasospasm<sup>a)</sup></p></td></tr><tr><td style="vertical-align:top; width:89.4pt"><p>Diseases of the airways, chest and mediastinum</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:102.0pt"><p>Dyspnoea<sup>*)</sup>,</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:132.0pt"><p>Pulmonary oedema<sup>*)</sup>,</p><p>Respiratory insufficiency<sup>*)</sup>,</p><p>Aspiration<sup>*)</sup></p></td></tr><tr><td style="vertical-align:top; width:89.4pt"><p>Diseases of the gastrointestinal tract</p></td><td style="vertical-align:top; width:84.0pt"><p>Vomiting,</p><p>Nausea</p></td><td style="vertical-align:top; width:102.0pt"><p>Abdominal pain</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:132.0pt"><p>Dysphagia,</p><p>Swelling of salivary gland,</p><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top; width:89.4pt"><p>Diseases of the skin and subcutis</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:102.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:132.0pt"><p>Skin diseases with blister formation (e.g. Stevens-Johnson or Lyell&#39;s syndrome),</p><p>Exanthema,</p><p>Erythema,</p><p>Hyperhidrosis,</p><p>Acute generalised exanthematous pustulosis, Drug reaction with eosinophilia and systemic symptoms</p></td></tr><tr><td style="vertical-align:top; width:89.4pt"><p>Skeletal musculature, connective tissue and bone disease</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:102.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:132.0pt"><p>Compartment syndrome after extravasation<sup>a)</sup></p></td></tr><tr><td style="vertical-align:top; width:89.4pt"><p>Diseases of the kidneys and urinary tract</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:102.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:132.0pt"><p>Renal function disturbance<sup>a)</sup>,</p><p>Acute renal failure<sup>a)</sup></p></td></tr><tr><td style="vertical-align:top; width:89.4pt"><p>General diseases and symptoms at the administration site</p></td><td style="vertical-align:top; width:84.0pt"><p>Pain,</p><p>Reaction at injection site (various, e.g. pain, sensation of warmth<sup>&sect;)</sup>, oedema<sup>&sect;)</sup>, inflammation of<sup>&sect;)</sup> and injury to soft tissue<sup>&sect;)</sup> in case of extravasation),<br />Sensation of heat</p></td><td style="vertical-align:top; width:102.0pt"><p>Oedema</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:132.0pt"><p>Malaise,</p><p>Chills,</p><p>Paleness</p></td></tr><tr><td style="vertical-align:top; width:89.4pt"><p>Examinations</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:102.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:84.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:132.0pt"><p>Changes in body temperature</p></td></tr></tbody></table><p>*) life-threatening and/or cases involving death have been reported</p><p>a) applies only for intravascular application</p><p>&sect;) only observed in the context of post-marketing reporting (unknown frequency of occurrence)</p><p>&nbsp;</p><p><em>Intravascular use</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">Side effects associated with the intravascular administration of iodinated contrast media are usually mild to moderate and transient in nature. Nevertheless, serious and isolated life-threatening reactions can occur that require rapid and effective emergency treatment.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left">Reactions to contrast media occur much more frequently and are more severe in the context of intravascular administration, than when administered into body cavities (intraductal, intracavitary and oral administration).</p><p style="margin-left:0in; margin-right:0in"><em>&nbsp;</em></p><p><em>Use in body cavities</em></p><p style="margin-left:0in; text-align:left">Since a small amount of contrast media can enter a blood vessel after intraductal or intracavitary administration, allergoid reactions such as those described for intravascular administration of contrast medium are also possible in association with intracavitary administration.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">Symptoms occurring in the context of body cavity imaging can vary according to the examined region and are generally elicited by the employed examination techniques. Most adverse events occur within a few hours of application in body cavities.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">Pain due to volume expansion may be experienced when filling body cavities with contrast media.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">In addition to the side effects described above, an increase in pancreatic enzymes and onset of pancreatitis, incl. necrotising pancreatitis, have been reported after <strong>ERCP examinations</strong>. The frequency of occurrence of these side effects is unknown, which may be due to an increase in pressure in the narrow pancreas ducts as a result of overfilling with Ultravist.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">Gastrointestinal complaints have been observed after oral administration.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s):</strong></p><p>The National Pharmacovigilance Centre (NPC).</p><p>Fax: + 966 - 11 - 205 - 7662.</p><p>SFDA call center: 19999.</p><p>E - mail: npc.drug@sfda.gov.sa.</p><p>Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in; text-align:left">Symptoms of an overdose can include water/electrolyte imbalance, renal failure, as well as cardiovascular and respiratory complications.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">The aim of overdose treatment is to maintain all vital functions and to immediately initiate symptomatic therapy as indicated. In the event of an accidental overdose, any possible water and electrolyte imbalance must be monitored, in addition to renal function.</p><p style="margin-left:0in; text-align:left">Ultravist can be dialysed.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in">Pharmacotherapeutic category: water-soluble, nephrotropic, low osmolar X-ray contrast medium (monomeric non-ionic X-ray contrast medium), ATC code: V08A B05</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">Iopromide, the contrast-enhancing substance in all Ultravist application methods, is a tri-iodinated, non-ionic, water-soluble X-ray contrast medium with a molecular weight of 791.12&nbsp;g/mol. Its contrasting properties are achieved with iodine that is stably bound in the molecule and which absorbs the X rays.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in; margin-right:0in; text-align:left"><u>Resorption/ distribution</u></p><p style="margin-left:0in; text-align:left">After intravenous application, plasma concentrations of iopromide drop rapidly due to distribution in the extracellular space and subsequent elimination. The total distribution volume under steady state conditions amounts to approx. 16&nbsp;L, which more or less corresponds to the volume of the extracellular space.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">Plasma protein binding is negligible (approx.&nbsp;1%). There is no evidence that iopromide can penetrate an intact blood brain barrier. Experimental studies in animals have shown that slight quantities of iopromide can pass the placenta barrier (&le;&nbsp;0.3% of the applied dose in rabbit foetuses).</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">After application in the bile and/or pancreatic ducts in the context of ERCP examination, iodated contrast media are systematically absorbed and achieve the maximum plasma concentrations within 1&nbsp;to 4&nbsp;hours post application. Maximum iodine concentrations in serum following an average dose of approx. 7.3&nbsp;g iodine were approx. 40&nbsp;times lower than maximum serum concentrations after the corresponding intravenous application.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left"><u>Biotransformation</u></p><p style="margin-left:0in; text-align:left">Iopromide is not metabolised.</p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left"><u>Elimination</u></p><p style="margin-left:0in; text-align:left">The terminal elimination half-life of iopromide amounts to approx. 2&nbsp;hours, irrespective of the administered dose.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">When used within the tested dosage range, the mean total clearance of iopromide is 106&nbsp;&plusmn;&nbsp;12&nbsp;mL/min, equivalent to a renal clearance of 102&nbsp;&plusmn;&nbsp;15mL/min. It follows that iopromide is excreted nearly exclusively via the kidneys. Only approx.&nbsp;2% of the applied dose is excreted with the faeces within 3&nbsp;days.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">In conjunction with intravenous injection, approx. 60% of the dose ─ and after 12&nbsp;hours on average &ge;&nbsp;93% of the dose ─ is excreted with urine after three hours. Excretion is more or less complete after a period of 24&nbsp;hours.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">After ERCP use in the bile and/or pancreatic ducts, iodine concentrations in serum returned to their original pre-application values within 7&nbsp;days.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left"><u>Linearity/non-linearity</u></p><p style="margin-left:0in; text-align:left">The pharmacokinetic properties of iopromide in humans change in proportion to the dose (e.g. C<sub>max</sub>, AUC) or are dose-dependent (e.g. V<sub>ss</sub>, t&frac12;).</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left"><u>Particularities in special patient groups</u></p><p style="margin-left:0in; text-align:left"><em>&nbsp;</em></p><p style="margin-left:0in; text-align:left"><em>Older patients (65&nbsp;years and older)</em></p><p style="margin-left:0in; text-align:left">Middle-aged patients (49-64&nbsp;years) and older patients (65-70&nbsp;years), who do not suffer from significant renal impairment exhibited a total plasma clearance of between 74&nbsp;and 114&nbsp;mL/min (middle-aged patient group averaged 102&nbsp;mL/min) and between 72&nbsp;and 110&nbsp;mL/min (older patient group averaged 89&nbsp;mL/min); i.e. only slightly lower values than those obtained for younger healthy persons (88&nbsp;to 138&nbsp;mL/min, mean 106&nbsp;mL/min). The individual elimination half-live values were situated between 1.9-2.9&nbsp;h and 1.5-2.7&nbsp;h. In comparison with the range 1.4-2.1&nbsp;h in young healthy volunteers, the terminal half-life period was similar. The slight differences can be explained by an age-related physiological reduction in the glomerular filtration rate.</p><p style="margin-left:0in; text-align:left"><em>&nbsp;</em></p><p style="margin-left:0in; text-align:left"><em>Paediatric patients</em></p><p style="margin-left:0in; text-align:left">The pharmacokinetic properties of iopromide have not been examined in a paediatric population (cf. section&nbsp;4.2).</p><p style="margin-left:0in; text-align:left"><em>&nbsp;</em></p><p style="margin-left:0in; text-align:left"><em>Patients with renal dysfunction</em></p><p style="margin-left:0in; text-align:left">In patients with impaired renal function, the plasma half-life time of iopromide is prolonged due to the reduced glomerular filtration rate.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">In patients with slight to moderate renal impairment (80&nbsp;&ge;&nbsp;CLCR&nbsp;&gt;&nbsp;30&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>), plasma clearance dropped to 49.4&nbsp;mL/min/1.73&nbsp;m<sup>2&nbsp;</sup>(CV&nbsp;=&nbsp;53%), as well as in patients with serious impairment (CLCR&nbsp;=&nbsp;30-10&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>), but not in dialysis-dependent patients, i.e. 18.1&nbsp;mL/min/1.73&nbsp;m<sup>2&nbsp;</sup>(CV&nbsp;=&nbsp;30%).</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">The mean final half-life time is 6.1&nbsp;h (CV&nbsp;=&nbsp;43%) in patients with slight to moderately severe renal function disturbances (80&nbsp;&ge;&nbsp;CLCR&nbsp;&gt;&nbsp;30&nbsp;mL/min/1.73&nbsp;m2) and 11.6&nbsp;h (CV&nbsp;=&nbsp;49%) in patients with severe renal function impairment.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">The quantity found in urine within 6&nbsp;h of the application amounted to 38% in patients with slight to moderate impairment, and 26% in patients with severely impaired renal function. In contrast, the value for healthy volunteers was 83%. Within 24&nbsp;h of applying iopromide, decomposition amounted to 60% in slight to moderately impaired patients and, 51% in severely impaired patients, in contrast to more than 95% in health volunteers.</p><p style="margin-left:0in; text-align:left">&nbsp;</p><p style="margin-left:0in; text-align:left">Iopromide can be eliminated by way of haemodialysis. Nearly 60% of the iopromide dose can be removed during a 3-hour dialysis session.</p><p style="margin-left:0in; text-align:left"><em>&nbsp;</em></p><p style="margin-left:0in; text-align:left"><em>Patients with hepatic dysfunction</em></p><p style="margin-left:0in; text-align:left">Excretion is not restricted in patients with liver function impairment, since iopromide is not metabolised and only 2% of the dose is excreted with the faeces.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in; margin-right:0in; text-align:left">Based on the results of conventional studies of pharmacological safety, toxicity in the context of repeated administration, reproduction and genotoxicity, the available preclinical data do not indicate any particular danger in humans.</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in; text-align:left"><u>Systemic toxicity</u></p><p style="margin-left:0in; text-align:left">The toxicity of iopromide is low. Single and repeated daily intravenous systemic tolerance studies in animals did not raise general concerns about single dose administrations of Ultravist in humans for diagnostic purposes.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in"><u>Reproduction toxicity, genotoxicity</u></p><p style="margin-left:0in">Investigations with iopromide have shown no evidence of embryotoxic, teratogenic or mutagenic effects.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in"><u>Local tolerance</u></p><p style="margin-left:0in">Local tolerance studies following single and repeated intravenous administration, as well as single intraarterial, intramuscular, paravenous, intraperitoneal, intrathecal and conjunctival individual applications have shown evidence that no, or only slight local adverse effects on blood vessels are to be expected in paravascular tissue, in the subarachnoid space, and in human mucous membranes.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">Studies examining contact sensitizing effects have shown no evidence of any contact-sensitizing potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium calcium edetate,</p><p>Hydrochloric acid (to adjust pH)</p><p>Trometamol</p><p style="margin-left:0in">Water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in">Due to possible incompatibility risks, Ultravist should never be mixed with any other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years

The chemical and physical stability of the ready-to-use preparation (solution for injection or infusion, or oral solution) has been demonstrated at 36-38º Celsius for a period of 10 hours. From a microbiological point of view, the ready-to-use preparation should be used immediately, unless the method used to open the container ensures that any risk of contamination can be ruled out.

If the ready-to-use preparation is not administered immediately, the operator must ensure that the remaining solution is used within the allotted time period and under the appropriate conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in">Protect from light and X rays.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">Do not store above 30&deg;C.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">Store Ultravist according to instructions and keep out of the sight and reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in">Vial: colourless, glass type&nbsp;I</p><p style="margin-left:0in">Bottle: colourless, glass type&nbsp;II</p><p style="margin-left:0in">Stopper: chlorinated butyl elastomer</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">Prefilled plastic cartridge:</p><p style="margin-left:0in">Canister: cycloolefin polymer, colourless, siliconised with silicone oil emulsion</p><p style="margin-left:0in">Plunger stoppers and tip closure: polyisoprene, type I, siliconised with silicone oil</p><p style="margin-left:0in">Solid core: polycarbonate</p><p style="margin-left:0in">Safety closure: polypropylene</p><p style="margin-left:0in">&nbsp;</p><p><u>Pack sizes</u></p><p>Ultravist-150:</p><p style="margin-left:0in">10&nbsp;bottles, each containing 50&nbsp;mL</p><p>&nbsp;</p><p>Ultravist-240:</p><p style="margin-left:0in">10&nbsp;bottles, each containing 50&nbsp;mL</p><p>&nbsp;</p><p>Ultravist-300:</p><p style="margin-left:0in">10&nbsp;vials, each containing 10&nbsp;mL</p><p style="margin-left:0in">10&nbsp;bottles, each containing 50, 75, 100, 150&nbsp;or 200&nbsp;mL</p><p style="margin-left:0in">8&nbsp;bottles, each containing 500&nbsp;mL for injectors</p><p style="margin-left:0in">2&nbsp;x&nbsp;5&nbsp;prefilled plastic cartridges, each containing 75, 100, 125&nbsp;or 150&nbsp;mL</p><p>&nbsp;</p><p>Ultravist-370:</p><p style="margin-left:0in">10&nbsp;bottles, each containing 50, 100&nbsp;or 200&nbsp;mL</p><p style="margin-left:0in">8&nbsp;bottles, each containing 500&nbsp;mL for injectors</p><p style="margin-left:0in">2&nbsp;x&nbsp;5&nbsp;prefilled plastic cartridges, each containing 75, 100, 125&nbsp;or 150&nbsp;mL</p><p>&nbsp;</p><p style="margin-left:0in">To ensure proper use of the prefilled plastic cartridges, please note the exact marking on the container.</p><p style="margin-left:0in">&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">Ultravist should be heated to body temperature prior to application.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">Ultravist<sup> </sup>is supplied as a ready-to-use, clear, colourless to pale yellow solution.</p><p style="margin-left:0in"><sup>&nbsp;</sup></p><p style="margin-left:0in">The contrast medium should be inspected visually prior to use. Because Ultravist is a highly concentrated solution, crystallisation may occur in rare cases (milky-turbid appearance and/or bottom sediment or swimming crystals). It is prohibited to use contrast media if severely discoloured, if particles (incl. crystals) are visible, or if the container is damaged.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">The contrast medium solution should not be drawn up into the syringe or into the infusion reservoir connected to the infusion device until just prior to starting the examination.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">The rubber stopper may only be pierced once in order to prevent significant quantities of micro-particles from entering the solution via the stopper. A long-tip cannula with a maximum diameter of 18&nbsp;G is recommended for piercing the stopper and for drawing up the contrast medium (special withdrawal cannulas with a side holes, e.g. Nocore-Admix cannulas, are particularly suitable).</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">Contrast media solutions for injection or infusion are meant for one-time use only. Any unused contrast media remaining after the examination procedure must be discarded and appropriately disposed of.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">If an automatic application system is used to administer a medicinal product, the medicinal product manufacturer must provide evidence of the suitability of any such planned use. The instructions for use of the medicinal products in question must be strictly followed. The use of automatic application systems is prohibited in babies and small children.</p><p style="margin-left:0in">&nbsp;</p><p style="margin-left:0in">The following rules apply when using prefilled plastic cartridges: contrast media should always be administered by qualified medical staff and the procedure conducted using the appropriate methods and apparatus. Sterile handling techniques must be strictly followed for all injections involving contrast media. Contrast media must be administered using the appropriate injector. Depending on the cartridge type, the required injector type is clearly marked on the container itself. Any pertinent manufacturer instructions must be strictly followed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bayer AG
D-51368 Leverkusen
Germany.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>